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SUMMARY 
 
The intestinal microbiota regulates physiological processes and maintains homeostasis in the 
gut. Accordingly, research is conducted to understand the factors influencing the 
composition of the intestinal microbiota. Dietary- and host-derived glycans have been shown 
to profoundly affect the growth of the intestinal microbiota. However, the specific link 
between glycans and intestinal microbiota remains unclear. The focus of this work was to 
determine how glycans regulate the intestinal microbiota and thereby influence the host 
mucosal immunity. 
 
Sialic acids, provided by milk oligosaccharides and mucosal glycans, are preferred nutrient 
sources of Escherichia coli in the intestine. We identified increased sialidase production by 
the commensal Bacteroides vulgatus during intestinal inflammation. This led to increased 
free sialic acid in the colon during inflammation thereby promoting the proliferation of E. coli. 
The proliferation of E. coli exacerbated inflammatory responses by stimulating the 
production of pro-inflammatory cytokines by intestinal dendritic cells. By inhibiting intestinal 
sialidases, the proliferation of E. coli was prevented and intestinal inflammation is attenuated. 
This finding demonstrates that sialic acid catabolism influences the intestinal microbiota and 
mucosal immunity. 
 
Furthermore, we investigated the links between the gut microbiota, their metabolites and 
mucosal immunity. The major bacterial fermentation products, namely short-chain fatty 
acids, have been measured and compared between healthy and colitogenic mice. A 
significant reduction of caecal short-chain fatty acids, especially butyrate, was observed 
during intestinal inflammation. This correlated with lower abundance of butyrate-producing 
bacteria such as Faecalibacterium prausnitzii and Eubacterium hallii. Additionally, by treating 
mice with antibiotics, intestinal inflammation was exacerbated whereas caecal short-chain 
fatty acid levels decreased. By exogenously supplying colitogenic mice with butyrate, 
inflammation was attenuated, therefore confirming the beneficial role of butyrate in 
regulating mucosal immunity. 
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Our studies demonstrate for the first time that host-derived glycosylation confers a critical 
growth advantage for E. coli during intestinal inflammation. Furthermore, by establishing the 
essential contribution of intestinal sialic acid and sialidase in mediating microbial dysbiosis, 
we define a fundamental mechanism by which E. coli proliferates in the gut, thereby 
unraveling a novel therapeutic target for the treatment of intestinal inflammation. Overall, 
our studies reveal potential opportunities for the treatment of inflammatory intestinal 
diseases by regulating glycan metabolic pathways and the gut microbiota. 
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ZUSAMMENFASSUNG 
 
Die intestinale Mikroflora reguliert einerseits physiologische Prozesse und andererseits sorgt 
es für Homöostase im Darm. Aufgrund dessen wird nach Faktoren geforscht, welche die 
Zusammensetzung der Mikroflora im Darm beeinflussen. Glykane sind eine wichtige 
Nahrungsquelle und beeinflussen das Wachstum der intestinalen Mikrobiota. Die exakten 
Zusammenhänge zwischen bestimmten Glykanen und den einzelnen Komponenten der 
Mikrobiota sind jedoch weiterhin unklar. In dieser Arbeit wird gezeigt wie Glykane die 
mikrobielle Zusammensetzung im Darm verändern und damit auch die Immunabwehr an den 
Schleimhäuten des Darms beeinflussen. 
 
Sialinsäuren stellen eine gute Nahrungsquelle für Escherichia coli dar. Im Darm stammen 
Sialinsäuren zum einten aus der Ernährung (z.B. Milch Oligosaccharide des Menschen) und 
zum anderen kommen sie in Schleimhaut produzierten Glykanen vor. Wir konnten feststellen, 
dass die Sialidase von Bacteroides vulgatus, während inflammatorischen Darmerkrankungen, 
in erhöhten Mengen vorhanden ist. Dies führte zu einem erhöhten Anteil an freien 
Sialinsäuren, welches wiederum die Vermehrung von E. coli förderte. Die erhöhte 
Proliferation von E. coli führte wiederum zu einem verstärkten inflammatorischen Zustand, 
aufgrund einer erhöhten Produktion an pro-inflammatorischen Zytokinen durch intestinale 
dendritische Zellen. Durch die Inhibition von intestinalen Sialidasen, wurde die Proliferation 
von E. coli verhindert und die Entzündung abgeschwächt. Diese Studie zeigt damit, dass der 
Katabolismus von Sialinsäuren die intestinale Mikrobiota und damit auch das Immunsystem 
an der Darmschleimhaut beeinflusst. 
 
Weiterhin wurde der Zusammenhang zwischen der Mikrobiota im Darm, ihrer Metaboliten 
und dem mukosalen Immunsystem untersucht. Die kurzkettigen Fettsäuren bilden den 
Hauptteil der bakteriellen Fermentationsprodukte und wurden daher in ihrer Menge 
zwischen gesunden und kolitischen Mäusen verglichen. In Kolitis erkrankte Mäuse war die 
Menge an kurzkettigen Fettsäuren, insbesondere Butyrat, im Dickdarm signifikant reduziert. 
Dies korrelierte mit geringeren Mengen an den Butyrat-produzierenden Bakterien 
Faecalibacterium prausnitzii und Eubacterium hallii, die wir beobachtet haben. Zusätzlich 
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konnte durch die Behandlung von Mäusen mit Antibiotika die Kolitis-Erkrankung verstärkt 
werden wobei die Menge an kurzkettigen Fettsäuren abnahm. Durch die exogene Versorgung 
von kolitogenen Mäusen mit Butyrat, wurde die Entzündung  verringert, wodurch die 
vorteilhafte Wirkung von Butyrat, auf die Regulation des Immunsystems der Schleimhaut, 
bestätigt werden konnte. 
 
Unsere Studien demonstrieren erstmalig, dass die Glykosylierung des Wirts, dem Bakterium 
E. coli einen kritischen Wachstumsvorteil ermöglicht. Weiterhin, zeigen wir, durch die 
Ermittlung der essentielen Rolle von intestinaler Sialinsäure und Sialidasen während 
mikrobieller Dysbiose, einen fundamentalen Mechanismus für die Proliferation von E. coli im 
Darm. Hiermit haben wir einen neue Möglichkeit aufgedeckt für die Behandlung von 
Kolitiserkrankungen. Insgesamt weist unsere Studie auf neue Möglichkeiten für die 
Behandlung von inflammatorischen Kolitiserkrankungen durch die Regulierung von 
Glykan-metabolischen Reaktionen und der intestinalen Mikrobiota. 
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ABBREVIATIONS  
 
3SL α2,3-sialyllactose 
4MuNeuNAc 2’-(4methylumbelliferyl)-α-D-N-acetylneuraminic acid 
6SL α2,6-sialyllactose 
CD Crohn’s disease 
CF Cecal fluid 
C.F.U. Colony forming unit 
DC Dendritic cell 
DGGE Denatured gradient gel electrophoresis 
DSS Dextran sulfate sodium 
Fuc Fucose 
Gal Galactose 
GalNAc N-acetyl galactosamine 
GALT Gut associated lymphoid tissue 
GI Gastrointestinal tract 
Glc Glucose 
GlcNAc N-acetylglucosamine 
HMO Human milk oligosaccharides 
HPAEC High performance anion exchange chromatography 
IBD Inflammatory bowel disease 
INF-γ Interferon gamma 
Ig Immunoglobulin 
IL Interleukin 
IRAK Interleukin 1 receptor-associated kinase 
IRF3 Interferon-regulatory factor 3 
Iκκ IκB kinase 
LPS Lipopolysaccharide 
M cell Microfold cells 
MHC Major histocompatibility complex 
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MLN Mesenteric lymph node 
MyD88 Myeloid differentiation primary response gene 88 
NanT Neuraminate transporter 
Neu5Ac N-acetylneuraminic acid 
Neu5Gc N-glycolylneuraminic acid 
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NLR Nucleotide-binding domain and leucine rich repeat containing 
receptor 
NOD Nucleotide-binding oligomerization domain 
PRR Pattern recognition receptor 
sIgA Secretory immunoglobulin A 
Sia Sialic acid 
ST St3gal4 glycosytransferase  
Stp Streptomycin 
Treg T regulatory cell 
TGF-β Transforming growth factor beta 
TH1 T helper 1 
TH2 T helper 2 
TLR Toll like receptor 
TNF-α Tumor necrosis factor alfa 
UC Ulcerative colitis 
Van Vancomycin 
WT Wildtype 
XF Cross-fostering 
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INTRODUCTION 
 
1. Nutrition and immune system 
 
Human milk is widely considered as a gold standard for the infant’s early nutrition. It 
provides all the components that are necessary for proper growth and development of 
neonates. Human milk contains diverse macronutrients including carbohydrates, proteins, 
lipids and other micronutrients such as vitamins and minerals. Besides nutritional benefits, 
human milk also contains multiple bioactive and immunomodulatory components. These 
bioactive components provide active and passive protection for neonates. Beneficial effects 
of breast-feeding are well documented in several studies, including reduced risks of 
infectious diseases, necrotizing enterocolitis (NEC) [1], food allergies and atopic diseases [2]. 
Moreover, breast-feeding also provides a long-lasting effect, as shown by a lower incidence 
of developing type II diabetes [3], metabolic syndrome diseases [4], and inflammatory bowel 
diseases (IBD) [5]. 
 
1.1 Nutritional components in milk 
 
The composition of human milk, unlike standardized formula, is dynamic and differs over the 
lactation period and between individuals. The main macronutrients of milk are 
carbohydrates, lipids, and proteins. The carbohydrate fractions in both formula and breast 
milk are mainly composed of the disaccharide lactose. However, human milk is also a rich 
source of unique milk oligosaccharides (HMOs) which are thus lacking in manufactured 
formula. The unique compositions and biological functions of HMOs will be discussed later 
(Ch 1.3-1.4). 
 
The protein fractions of human milk are mainly divided into soluble whey protein and 
insoluble casein [6]. Whey protein is the collection of globular proteins that mainly consists 
of β-lactoglobulin, α-lactalbumin, serum albumin, and immunoglobulin. Soluble whey 
proteins are readily digestible for infants and are also abundant sources of essential amino 
acids [6-7]. Casein is the collection of phosphoproteins, which constitute about 80% of total 
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milk proteins in bovine milk, and mainly act as a mineral carrier for calcium and phosphorus 
in promoting their digestibility in the stomach. Casein-derived peptides have been shown to 
possess antimicrobial [8], antioxidant, [9] and antihypertensive activities [10].  
 
The lipid fractions of milk are the major energy sources for neonates, accounting for about 
50-60% of the total calories intake [11]. It consists of mainly triacylglycerol (~97%), 
diacylglycerol (2%), free fatty acids (~1%), and cholesterol (<0.5%) [12]. The composition of 
lipids in milk is highly dependent on maternal diet, therefore, varies between individuals and 
over lactation period. Recently, fatty acids have received more attention because of their 
health benefits to the development of neonatal nervous system and immune system. The 
most abundant fatty acids in human milk are oleic acid (C18:1) and palmitic acid (C16:0) [13]. 
Moreover, human milk is also rich in polyunsaturated fatty acids (PUFAs) including omega-3 
and omega-6 fatty acids. They are essential fatty acids that can only be acquired from the 
diet, but cannot be biosynthesized de novo. The importance of PUFAs is shown by the 
essential roles of docosahexaenoic acid (DHA) and arachidonic acid (AA) in proper 
development of brain and nervous system [14], and the immunomodulatory effect of DHA in 
treatment of inflammatory bowel disease [15]. 
 
1.2 Bioactive components in milk 
 
Human milk is rich in bioactive components, which include various growth factors and 
immunological factors. These bioactive components contribute to active and passive 
protection for neonatal immune system which is not yet fully developed. Moreover, 
immunological factors are responsible for modulating the immune tolerance and maintaining 
homeostasis of postnatal innate and adaptive immunity. The multiple functions of bioactive 
components in human milk are summarized in Table 1. Human milk contains various 
hormones and growth factors that support growth and development in systemic level. 
Epidermal growth factor (EGF), which is enriched in colostrums, plays multiple roles in 
promoting maturation of the intestinal mucosa. EGF promotes the proliferation of 
enterocytes, facilitates mucosal repair, and also provides protection against NEC [16]. 
Insulin-like growth factor also promotes intestinal epithelial growth and regulates glucose 
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metabolism [17]. Neuronal growth factor supports neuronal outgrowth and survival. 
Growth-supporting hormones, such as erythropoietin (EPO), reaches receptors in the 
intestinal tract and stimulate the erythrocytes production in bone marrow [18]. Other 
hormones like calcitonin and adiponectin regulate calcium metabolism and energy 
conversion, respectively. 
 
Table 1. Bioactive components and their functions in human milk (adapted from [19-20]). 
 
EGF, epidermal growth factor; VEGF, vascular endothelial growth factor; NGF, nerve growth factor; IGF, 
insulin-like growth factor; AA, arachidonic acid; DHA, docosahexaenic acid; LCPUFA, long-chain 
polyunsaturated fatty acids; HMOs, human milk oligosaccharides; MIF, macrophage migration 
inhibitory factor; CCL5, C-C Chemokine ligand 5; MCP-1, monocyte chemotactic protein-1 
 
Human milk contains a wide range of immunological factors including immune cells, 
immunoglobulins, antimicrobial proteins and cytokines which mutually facilitate the 
development of infant’s immunity. Immune cells including macrophages (55-60%), 
neutrophils (30-40%), and lymphocytes (5-10%) remain viable in breast milk [21]. 
Macrophages and neutrophils provide a direct pathogen clearance activity and activate the 
immune system. In addition, milk-derived lymphocytes have been shown to traverse the 
Growth & development
• Growth factors
EGF, VEGF, NGF, IGF
Erythroprotein
• Hormones
Calcitonin, somatostatin
Adiponectin, Leptin
• Cholesterol and Fatty acid
(AA, DHA, LCPUFA)
• Ganglioside, HMOs
• Vitamins
Antimicrobial activity
• Immunoglobulins
(soluble IgA, IgG, IgM)
• Antimicrobial proteins
Lactoferrin
α-Lactalbumin, κ-Casein
Defensin
Complement 
Lysozyme
• Soluble decoy receptors 
sTLR, CD14
• HMOs and Mucins
Immunomodulation
• Immune cells
(Macrophage, Neutrophil, 
Lymphocyte)
• Cytokines
- pro-inflammatory
(IL-1β, IL-6, IL-8, TNFα, IFNγ)
- anti-inflammatory
(IL-10, TGFβ)
• Chemokines
MIF, CCL5, MCP-1, MCP-3
• Receptors
sTLR, IL-1R, IL-6R, TNF-R
Bioactive components  and functions in milk
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neonatal intestine and promote T cell development as shown by an increase size of thymus 
in breast-fed infants [22]. At birth, immunoglobulin levels are very low in the intestinal 
mucosa of neonate [23]. Therefore, the early response to dietary and microbial antigens in 
neonatal mucosal immune system relies on maternal milk. Secretory immunoglobulin A 
(sIgA), which constitutes 90% of total immunoglobulins in milk, inhibits the adherence of 
enteric pathogens, neutralizes toxins, and induces the immune tolerance. Other components 
of innate immunity exhibit direct bactericidal activity such as lactoferrin, lysozyme, 
α-lactalbumin, and defensins [24]. Soluble decoy receptors like sTLR2 and sCD14 [25-26] also 
prevent pathogen adherence and infection [27]. 
 
Cytokines and chemokines also show immunomodulating activities. The primary source of 
milk cytokines is the mammary gland, whereas small amounts of cytokines are secreted by 
leukocytes [24]. A variety of cytokines and chemokines in human milk regulate the induction 
of pro- or anti- inflammatory responses [28]. Pro-inflammatory cytokines like IL-1β, IL-6, IL-8, 
and TNF-α mediate inflammatory process and clearance of pathogens [29]. 
Anti-inflammatory cytokines, such as IL-10 and TGF-β, dampen the excessive inflammatory 
responses and promote healing of the intestinal mucosa [30-31]. Corresponding soluble 
receptors and cytokine antagonists (e.g. IL-1R, IL-6R, TNFR) also contribute to 
anti-inflammatory properties [32]. Chemokines like CCL2-5 and CXCL1-3 families are also 
identified in milk and facilitate the recruitment of leukocytes to the site of infection [28]. 
Overall, bioactive components and immunological factors not only provide direct health 
benefits but also instruct the development of postnatal immune system.  
 
1.3 Composition of milk oligosaccharides 
 
The composition of human milk is unique among mammals because of the high abundance 
and complexity of human milk oligosaccharides (HMOs) [33]. HMOs are composed of five 
main monosaccharides, including glucose (Glc), galactose (Gal), N-acetylglucosamine 
(GlcNAc), N-acetylneuraminic acid (Neu5Ac) and fucose (Fuc). The biosynthesis of HMOs 
depends on the expression of glycosyltransferases in mammary gland, and typically begins 
with the formation of a lactose core. Lactose or the elongated oligosaccharides can be 
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further fucosylated in α1-2, α1-3, α1-4 linkages and sialylated in α2-3, α2-6 linkages at the 
terminal positions. The proportion of fucosylated, sialylated, and neutral HMOs in human 
milk ranging from 35-50%, 12-14%, and 42-55%, respectively and varies between individuals 
[34]. The structural diversity of HMOs are summarized in Figure 1. 
 
The majority of HMOs are not digestible and absorbable in the human intestine due to lack 
of suitable glycosidase enzymes in the GI tract. Therefore, a major question is why does the 
mammary gland synthesize energetically costly HMOs that do not directly provide a 
nutritional benefit to the infants? Originally, HMOs were defined as prebiotic factors that 
selectively enrich a group of bifidobacteria, which confer beneficial advantages to the 
breast-fed infants. Nowadays, accumulating evidences suggest that HMOs not only function 
as a metabolic source for desired bacteria but are also involved in regulating gut homeostasis 
and mucosal immunity. The postulated beneficial effects of HMOs can be divided into the 
following categories: (1) HMOs serve as prebiotics promoting the colonization of beneficial 
bacteria; (2) HMOs serve as soluble decoy receptors preventing the attachment and infection 
of pathogens; (3) HMOs modulate intestinal epithelial cell functions; (4) HMOs are critical 
nutrients for brain development. 
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Figure 1. Structural diversity of human milk oligosaccharides (HMOs) (Adapted from [35]). HMOs 
consist of a lactose core linked to lacto-N-biose or to N-acetyllactosamine with repeating units. 
Lactose can be sialylated or fucosylated by different linkages to form trisaccharides 3SL, 6SL, 2FL, and 
3FL. Lactose can also be elongated in repeats of lacto-N-tetrose (LNT) or N-acetyllactosamine (LNnT). 
Elongated type I or II chains can be fucosylated in different linkages to form a variety of structural 
isomers. The elongated chains can be sialylated in different linkages to form structural isomers.  
 
1.4 Functions of milk oligosaccharides 
 
1.4.1 HMOs function as prebiotics 
 
Prebiotics are ingredients, which provide as selective nutrient sources for a desired group of 
commensal bacteria that contribute to the health of a host. HMOs are resistant to acidic and 
enzymatic hydrolysis in the stomach and small intestine, thereby the majority of HMOs can 
reach the colon that harbors the densest microbial community in the GI tract. To utilize 
HMOs, bacteria require an array of glycosidases, For example, α-fucosidase or α-sialidase are 
responsible for the initial step for cleaving terminal fucose or sialic acid on HMOs. Afterward, 
β1-3 β1-3
β1-4 β1-6
β1-4
n= 0-15
Lacto-N-biose
Lactose
β1-4
α1-2
β1-4
α1-3
2’-FL                    3FL
3’-SL                    6’-SL
β1-4
α2-3
β1-4
α2-6
β1-4
β1-3
β1-3
β1-4
β1-3
β1-4
β1-4
β1-3
β1-3
β1-4
β1-6
LNT (Type I)              LNnT (Type II)
LNH
β1-4
β1-3
β1-3 LNFP I                                            LNFP II                                              LNFP III                          
α1-2
β1-4
β1-3
β1-3
α1-4
β1-4
β1-3
β1-4
α1-3
LST a                                            LST b                                              LST c
β1-4
β1-3
β1-3
α2-3
β1-4
β1-3
β1-3
α2-6
β1-4
β1-3
β1-4
α2-6
Glucose
Galactose
N-acetylglucosamine
Sialic acid
Fucose
Monosaccharide key
N-acetyllactosamine
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the remaining structures are available for digestion by β-hexosaminidase or lacto-N-biosidase 
to generate monosaccharides and disaccharides. Intestinal bacteria which possess the 
required glycosidases thus receive a growth advantage on colonization of the host colon.  
 
It has been shown that bifidobacteria are predominant species in the gut of breast-fed 
infants compared to formula-fed infants [36-37]. Bifidobacterium longum subsp. Infantis (B. 
infantis) and B. breve have been shown to grow on HMOs as a single carbon source in vitro 
[38-39], and preferentially utilize fucosylated and sialylated HMOs. Additionally, B. bifidum 
grows slower on HMOs compared to B. infantis [40] while B. longum subsp. only grow on 
lacto-N-teteraose [41]. The different growth profiles among bifidobacteria suggest that they 
metabolize HMOs through different pathways. It has been described that B. infantis and B. 
breve encode glycans transporters and intracellular glycosidases, indicating that HMOs are 
internalized and metabolized in cells [42-43]. By contrast, B. bifidum expresses extracellular 
glycosidases that cleave HMOs and then transport the disaccharide into cell. In addition to 
bifidobacteria, recent studies have shown that some Lactobacillus sp. are able to utilize 
fucosylated HMOs [44], and several Bacteroides spp. also demonstrate a robust growth on 
HMOs [45-46]. The dominance of bifidobacteria in breast-fed infants limits the nutrient 
supply for other bacteria, thereby preventing the growth of potentially pathogens in the 
newborns. Furthermore, bifidobacteria can protect from enteropathogenic infection through 
the production of acetate [47] and promote vitamins synthesis in mediating a trophic effect 
on the host intestinal epithelium [48]. Additionally, bifidobacteria stimulate mucosal 
immunity by enhancing IgA production against pathogens, like rotavirus [49]. Potential 
effects of prebiotics are summarized in Figure 2. 
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Figure 2. Effects of prebiotics in gastrointestinal tract (Adapted from [50]). Prebiotics promote the 
colonization of the gut by beneficial bacteria. These bacteria modulate gut homeostasis through 
multiple mechanisms, including the prevention of pathogens adherence, the production of beneficial 
nutrients (SCFAs, minerals and vitamins), and immunomodulation.  
 
1.4.2 HMOs prevent pathogens and toxins adhesion 
 
Adhesion of pathogens to the epithelial surface is an initial step of microbial infection. This 
binding is mediated through microbial lectin-glycan interaction [51]. Many HMOs share 
structural similarities to cell surface glycans because of common expression patterns of the 
glycosyltransferases [52]. Therefore, a variety of HMOs can serve as soluble decoy receptors, 
which reduce the adherence of pathogens on intestinal epithelial surface and prevent the 
ensuing infection. For instance, a recent study has shown that supplementation of exogenous 
fucosylated oligosaccharides reduces the binding of Campylobacter jejuni to intestinal 
epithelial cells in vitro, thereby inhibiting their colonization of the gut in mice [53]. 
Additionally, a human clinical study based on 93 mother-infant pairs suggested that infants 
exposure to higher concentration of 2FL correlated with a lower incidence of C. 
jejuni-associated diarrhea, and the protection against calicivirus diarrhea was associated with 
lacto-N-difucohexaose I (LDFH-I) [54]. This study has demonstrated that specific HMOs can 
Prebiotics
Colonic microbiota
↑ Bifidobacteria
↑ Lactobacilli
↑ Bacteroides spp
Reduced pH
Enhanced mineral 
compounds absorption
(Ca2+, Mg2+, Fe3+ ions)
Immunomodulation
(e.g. IgA secretion)
Antimicrobial effect
Reduction of pathogen 
infections
Increase fecal 
bulking and output
Energy source for 
colonocytes and 
lymphoid cells
Fermentation of 
oligosaccharides to SCFA 
and lactic acid
Not digested or absorbed in 
stomach or small intestine
Alter cell surface 
glycosylation
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protect infants from specific pathogens induced diarrhea. However, studies also suggested 
that the protective effect of fucosylated oligosaccharides differs among individuals due to 
polymorphisms in the responsible fucosyltransferase genes [55-56].  
 
In addition to fucosylated oligosaccharides, sialylated oligosaccharides are also abundant in 
human milk and play pivotal roles in neonatal protection. For instance, 3SL has been shown 
to inhibit the binding of bacteria or bacterial toxins, such as Helicobacter pylori, cholera toxin 
and E. coli enterotoxin to mucosa surface [57-58]. Disialyllacto-N-tetraose (DSLNT) has been 
also shown to prevent neonatal rats from NEC [59-60], and low level of DSLNT in maternal 
milk are implicated in the high incidence of developing NEC in the newborns. These 
anti-adhesive effects are not limited to bacterial infections but also observed in preventing 
virus infections, such as HIV [61-62], rotavirus [63], and norovirus [64]. Additional HMOs and 
other glycan structures inhibit the binding of pathogens are summarized in Table 2.  
 
On the basis of these in vitro and in vivo studies, glycan structures which block specific 
pathogen adhesion are potential therapeutics against bacterial or virus infection. As a result, 
supplementation of beneficial oligosaccharides in infant’s formula has recently received 
considerable interest to prevent the pathogenic infection in neonates. Advanced in 
large-scale synthesis of oligosaccharides has greatly facilitated the progression of clinical 
research. 
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Table 2. Pathogen recognition of host glycan receptors (Adapted from [58]).  
Glycan receptor Microorganisms Bacterial toxins 
α2,3 sialyllactose S-fimbriated E. coli 
Helicobacter pylori  
Rotavirus 
Botulinum toxin B 
Cholera toxin AB5 
Staphylococcal enterotoxin 
Sia (α2,3) derivatives Influenza virus A and B 
Polyomavirus 
 
Sia (α2,6) derivatives Influenza virus A and B Pertussis toxin 
Sia (α2,8) derivatives  Tetanus toxin 
Sialylated oligosaccharides Streptococcus suis 
Enterotoxigenic E. coli (ETEC) 
Uropathogenic E. coli (UPEC) 
 
Fucosylated oligosaccharides Campylobacter jejuni 
Clostridium difficile  
Vibrio cholerae 
E. coli enterotoxin 
Glycosphingolipid 
GM1, GM2, GM3 (α2,3Sia) 
GM1, GD1, GT1b 
S-fimbriated E. coli 
 
Cholera toxin AB5 
Heat-labile Enterotoxin 
Botulinum toxin  
 
1.4.3 HMOs modulate intestinal epithelial cell responses 
 
Milk oligosaccharides directly modulate host intestinal epithelial cell functions by regulating 
cell surface glycosylation. Exposure of human colorectal epithelial Caco-2 cells with 3SL 
reduced the expression of sialyltransferases, therefore decreased α2,3- and α2,6-linked 
sialylation on the cell surface [65]. As a result, the changes of surface glycans reduced 
adhesion of enteropathogenic E. coli by 50% in vitro. In addition, milk oligosaccharides have 
also been shown to influence cell differentiation, proliferation and apoptosis [66]. 
Stimulation of intestinal epithelial cells (e.g. HIEC, HT-29, and Caco-2) with neutral or acidic 
milk oligosaccharides yielded a dose-dependent cell cycle arrest by inducing epidermal 
growth factor receptor signaling and cyclin B expression [67]. The results suggested that 
HMOs inhibit cell proliferation and cell cycle dynamic through mitogen-activated protein 
kinase (MAPK) signaling. However, whether this growth inhibition effect on intestinal cells 
correlates with the beneficial outcomes of breast-feeding requires further investigation. A 
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more recent study also demonstrated that 2FL and 6SL reduce cell maturation in an epithelial 
model of crypt-villus axis, suggesting a specific role of HMOs in mediating cell differentiation 
and maturation in the gut [68]. Overall, these observations strongly suggest that HMOs 
interact with epithelial cells, affect host gene expression and modulate cell differentiation 
and proliferation. However, whether such in vitro studies can translate to benefits for 
breast-fed infants remain to be investigated. 
 
1.4.4 HMOs support development of the nervous system 
 
Accumulating evidences suggest that sialic acid is an essential nutrient for brain 
development and cognition during pre- and post-natal stages [69]. Newborns have a lower 
capacity for the de novo synthesis of sialic acid that does not meet the high demand for rapid 
neural development [69]. Dietary sialic acid, may therefore facilitates neural development. 
Human milk is a rich source of sialylated glycans and sialic acid. Sialic acid is absorbed across 
the mucosa of the small intestine, and transported into the bloodstream [70-71]. 
Furthermore, sialic acid can be taken and utilized by a variety of human cells including 
epithelial, skin fibroblasts and neural cells [72] for synthesis of sialoconjugates. Additionally, 
a recent study demonstrated that gangliosides and sialylated glycoproteins are significantly 
higher in the brains of breast-fed infants compared to formula-fed infants, indicating the 
dependence of sialic acid on brain development [73]. Gangliosides and neural cell adhesion 
molecule (NCAM) are the most investigated sialoconjugates involved in neonatal brain 
development. Numerous studies support their involvements in mediating synaptic 
remodeling, neuronal plasticity, neural circuit formation and adhesive interaction during 
brain development [69, 74]. Nevertheless, whether sialylated HMOs are the primary sialic 
acid source that uphold brain development in breast-fed infants remains to be elucidated. 
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2. The gastrointestinal tract and mucosal immune system 
 
2.1 Components of mucosal immune system  
 
Human gastrointestinal tract is covered with a mucosal layer which directly and constantly 
exposed to dietary antigens and gut microbiota. Therefore, mucosal immune system requires 
appropriate mechanisms to distinguish commensal bacteria or food antigens from the 
pathogenic microorganisms. This complex interplay between the mucosal immune system 
and microbiota is mediated by intestinal epithelial cells (IECs) and gut-associated lymphoid 
tissues (GALTs) (Figure 3). 
 
 
Figure 3. Intestinal epithelium barrier and GALTs (Adapted from [75-76]). The intestinal epithelial 
layer contains enterocytes, mucus-secreting goblet cells, antimicrobial proteins-releasing Paneth cells, 
and antigen delivering-microfold cells (M cells). M cells deliver antigens from the lumen to the 
subepithelial area in the Peyer’s Patch where dendritic cells (DCs) recognize the antigens and present 
to T cells. Activated DCs and lymphocytes migrate via afferent lymph to the mesenteric lymph node 
(MLN). In MLNs, lymphocytes mature and enter systemic circulation and back to lamina propria (LP). 
LP macrophages kill bacteria directly through phagocytosis, and LP plasma B cells secrete IgA 
triggering antigen-specific immune response. 
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IECs serve as a physical barrier, separating luminal antigens from the underlying immune 
tissues and blocking the entry of microbes into the lamina propria. IECs consist of various 
specialized cells which differentiate from intestinal stem cells within the crypts. Enterocytes, 
the major components of IECs, are involved in nutrient absorption and transcytosis. 
Microfold cells (M cells) mediated antigens delivery from lumen to lymphoid tissues. 
Enteroendocrine cells produce hormones in regulating luminal sensing and secretions. 
Goblet cells and Paneth cells provide passive protection by secreting mucins and 
antimicrobial proteins, respectively [77].  
 
GALTs are a collection of lymphoid tissues where antigens are taken up and processed. GALTs 
play critical roles in mediating the inflammatory response and immune tolerance. GALTs 
consist of both organized structures, such as mesenteric lymph nodes (MLNs), Peyer’s patch, 
and the dispersed isolated lymphoid follicles (ILFs) which are enriched in lymphocytes, 
dendritic cells, and macrophages. The activation of mucosal immunity begins with antigen 
uptake by M cells from intestinal lumen to Peyer’s patch where the antigens are further 
processed by antigen-presenting cells (APCs), and presented to naive T and B cells. 
Lymphocytes then migrate via afferent lymphatic vessels to the MLNs, where T cells and B 
cells mature and differentiate. Finally, activated lymphocytes enter the systemic circulation 
and travel back to lamina propria triggering antigen-specific immune responses [76]. The 
proper cooperation between IECs and GALTs contributes to intestinal homeostasis. 
Specifically, the homeostasis is accomplished through the secretion of mucus and 
antimicrobial proteins, and by the activation of both innate and adaptive immunity. 
Disruption in the balance of mucosal tolerance yield allergies, autoimmune diseases, and 
chronic inflammatory disorders [78]. 
 
2.2 Mucus layer  
 
The intestinal epithelium is covered with a viscous gel-like layer of mucus. This mucus layer 
consists of abundant mucins glycoproteins, antimicrobial peptides, and immunoglobulins 
(IgA) which work together to maintain intestinal homeostasis. Mucus is continuous along the 
GI tract and organized in two distinct layers. The loosely adherent outer layer represents the 
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first-line of defense against the external environment. The inner-stratified mucus layer, firmly 
adherent to epithelial cells, is resistant to bacterial penetration. Both the secreted and 
adherent mucus layer continually renew across the GI tract, thereby inhibiting pathogens 
adherence and assisting pathogens clearance [79].  
 
Mucins, secreted by Goblet cells, are the major components of mucus. To date, twenty-one 
mucin genes have been identified in the human genome and can be divided into secreted 
mucins and membrane-bound mucins [80]. Secreted mucins contribute to the elastic 
properties and assemble to a web-like structure of mucus gel. Membrane-bound mucins are 
expressed on the apical membrane of IECs and contribute to the viscous properties of mucus. 
Together, mucins create a physical and chemical barrier to prevent the direct contact of 
bacteria and toxins from the host tissues. Therefore, detection of bacteria in proximity of 
epithelial cells is a sign of impaired mucosal barrier, which can lead to bacterial translocation 
and subsequent inflammation [81-82]. For instance, MUC2-deficient mice are susceptible to 
colitis resulting from a direct contact of IECs with intestinal bacteria [83]. Decreased 
production of MUC2 has also been documented in patients with ulcerative colitis [84].  
 
The extensive glycosylation of mucins confers protection from proteolytic digestion. 
Carbohydrates represent more than 80% of the molecular mass of mucins [85]. These glycans 
are clustered into O-glycosylation domains of proteins rich in repeating serine and threonine. 
In addition to O-glycans, mucins carry a relative minor amount of N-linked glycans [81]. The 
common O-glycans on mucins are summarized in Figure 4. Sulfation and sialylation are 
common terminal modifications that contribute to the highly negative charge of mucins. The 
terminal O-glycans of mucins are highly heterogeneous and vary between species and tissue 
locations. For instance, human intestinal mucins display an increasing gradient of sialic acid 
and a decreasing gradient of fucose across ileum to colon [86]. Moreover, altered mucin 
glycosylation has been associated with bacterial infection and various disease progression 
[87]. Impaired O-glycosylation on core 1, core 2, and core 3 structures (Figure 4) of intestinal 
mucins increase the susceptibility of mice to colitis development [88-90]. 
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Figure 4. O-linked glycans on mucins (Adapted from [81]). O-linked glycosylation of mucins was 
initiated by the addition of N-acetyl-galactosamine (GalNAc) to the hydroxyl group of serine and 
threonine. GalNAc residue can be extended with Gal and GlcNAc and form 4 common core structures. 
These core structures can be further elongated with variable N-acetyllactosamine (LacNAc) chains, 
and terminated by Gal, Fuc or Neu5Ac. The terminal structures form histo-blood group antigens (A, B, 
H) and Lewis antigens (Le
a
, Le
b
, Le
x
, Le
y
) Fuc, fucose; Neu5Ac, N-acetylneuraminic acid; Gal, galactose; 
GalNAc, N-acetylgalactosamine; GlcNAc, N-acetylglucosamine. 
 
2.3 Antimicrobial proteins  
 
A second immune component contributing to the intestinal barrier are antimicrobial proteins 
(AMPs) secreted by IECs and immune cells. AMPs function as effectors of innate immunity to 
directly kill or inhibit the growth of microorganisms in the gut mucosa. The characteristics of 
major AMP families in the intestine are summarized in Table 3. Most AMPs target the 
microbial cell wall and cell membrane. For instance, lysozyme kills bacteria through 
enzymatic attack on the cell wall by hydrolyzing the glycosidic linkages of peptidoglycans [91]. 
Phospholipase A2 kills bacteria by hydrolyzing bacterial membrane phospholipids [92]. Other 
AMPs, such as lipocalin and calprotectin possess high metal chelating properties, depriving 
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essential nutrients of bacteria from the environment, thereby limiting bacterial growth in the 
gut mucosa [91].  
 
Defensins are cysteine-rich cationic proteins representing the major family of AMPs. 
Defensins are classified into α- and β-defensins according to the distribution of cysteines and 
disulfide bonds. Human α-defensins include human neutrophil peptides (HNP1-4), which are 
mainly secreted by neutrophils in the lamina propria [93], and HD5-6, which are expressed 
by Paneth cells. Human β-defensins (hBD1) are constitutively expressed by colonic epithelial 
cells. By contrast, hBD2 to 4 are secreted in response to external stimuli including various 
microorganisms and cytokines [94]. For instance, the induction of hBD2 is mediated by 
proinflammatory cytokines including IL-1β and TNF-α [95]. Among the defensins, hBD3 
displays a potent and broad spectrum of antimicrobial activity because of its high positive 
net charge [96], whereas hBD1 exhibits enhancing antimicrobial activity after reduction of 
disulfide bonds in anaerobic condition [97]. Besides antimicrobial activity, defensins have 
additional immunomodulatory activities as chemoattractants for leukocytes recruitment to 
the site of infection [98]. For instance, hBD1-3 facilitate the recruitment of memory T cells 
and immature DCs [99] while hBD3 and hBD4 mediate monocytes chemotaxis [100-101]. 
Additionally, defensins stimulate the proliferation of intestinal epithelial cells, and neutralize 
lipopolysaccharide (LPS) by preventing its oligomerization and receptor binding [102].  
 
Overall, the multiple functions of AMPs are essential for intestinal homeostasis. As a result, 
impaired production of AMPs is associated with intestinal dysbiosis, susceptibility to 
pathogenic infections and multiple inflammatory disorders [91, 103].  
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Table 3. Major antimicrobial protein families in the intestine (Adapted from [91]). 
Family proteins Mechanism of action Tissue 
expression 
Cellular expression 
α-defensin HD5-6 (in humans) 
Cryptdins (in mice) 
Membrane disruption Small intestine Paneth cells, 
neutrophils, 
macrophages 
β-defensin BD1-3 Membrane disruption; 
lipid II binding 
Large intestine,  Enterocytes 
Calprotectin  Metal chelation Abscesses Neutrophils 
Cathelicidin LL37 (in human) 
CRAMP (in mice) 
Membrane disruption Large intestine  Neutrophils, mast 
cells 
C-type lectin HIP/PAP (in human) 
REG3γ (in mice) 
Peptidoglycan 
recognition 
Small Intestine Paneth cells, 
enterocytes 
Galectin GAL4, GAL8 Unknown Intestine Epithelial cells 
Lipocalin Lipocalin 2 Iron chelation  Intestine Macrophages, 
epithelial cells 
Lysozyme  Hydrolysis of cell wall 
peptidoglycan 
Intestine 
secretions 
Paneth cells 
Phospho- 
lipase A2 
 Hydrolysis of membrane 
phospholipids 
Intestine 
secretions 
Paneth cells, 
macrophages 
BD, β-defensin; CRAMP, Cathelicidin-related antimicrobial peptide; GAL, galectin; HIP/PAP, hepatointestinal 
pancreatic/pancreatitis-associated protein; REG3γ, regenerating islet-derived protein 3γ  
 
2.4 Innate immunity  
 
Innate immunity is the first response to acute inflammation and also plays a regulatory role 
in adaptive immunity [104]. Innate immune cells consist of NK cells, mast cells, granulocytes 
(neutrophils, eosinophils, and basophils), and mainly DCs and macrophages in the gut 
mucosa. Neutrophils are the most abundant type of phagocytes, representing about 50% of 
circulating leukocytes, and are the first wave of cells to arrive to the sites of infection. They 
contribute to the fast clearance of pathogens by phagocytosis and release of granular 
proteins, but also secrete cytokines (IL-1, IL-6, IL-12, TNF-a) and chemokines which recruit 
and activate other immune cells. DCs have been characterized into a diverse subset based on 
the differential expression of cell markers (CD11b, CD11c, CD103) and chemokines receptors 
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(CCR7, CX3CR1). DCs exhibit phagocytic activity and antigen presenting activity, hence 
promoting the differentiation and maturation of lymphocytes into effector cells. Intestinal 
DCs are also responsible for inducing immune tolerance to commensal bacteria through 
induction of regulatory T cells and IgA-secreting B cells [105]. Macrophages present in lamina 
propria also exhibit high phagocytic and bactericidal activity through production of AMPs and 
reactive oxygen species [106]. Macrophages produce large amounts of pro-inflammatory 
cytokines such as IL-1β, IL-6, and TNF-α that recruit neutrophils and activate T cells during 
inflammation. By contrast, under normal conditions, intestinal macrophages produce 
anti-inflammatory cytokines such as IL-10, TGF-β, and retinoic acid promoting intestinal 
homeostasis [107]. 
 
The ability of innate immune cells to distinguish self- from non-self antigens relies on the 
expression of pattern recognition receptors (PRRs). PRRs are responsible for sensing the 
distinct microbial molecules, termed pathogen-associated molecular patterns (PAMPs), and 
the endogenous molecules released from damaged tissues, termed damage-associated 
molecular patterns (DAMPs) [108]. PAMPs are components specifically found in microbes, 
such as modified nucleic acids (bacterial or viral DNA and RNA), proteins (flagellin, profilin, 
envelope proteins), carbohydrates (LPS, zymosan, peptidoglycans) and lipoproteins (diacyl-, 
triacyl-lipoprotein). Because PAMPs are essential for the survival of microbes, these highly 
conserved molecular patterns represent ideal targets for innate immune cells. Exposure of 
PRRs to their ligands activates intracellular signaling cascades in immune cells, which induce 
a variety of immune responses aiming at the elimination of pathogens. Thus far, PRRs are 
divided into secreted, cytoplasmic, and transmembrane receptors based on their cellular 
localization. The major groups of PRRs and their microbial ligands are summarized in Table 4.  
 
(1) Secreted PRRs include collectins, ficolins, pentraxins, and complement receptors. These 
receptors are involved in the activation of complement system, microbial opsonization, and 
phagocytosis. For instance, collectin and pentraxin can bind to a wide range of microbial 
carbohydrate epitopes or membrane phosphocholine, and then lead to the activation of 
complement system and phagocytosis [109-110].  
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(2) Cytoplasmic PRRs include the retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) 
and nucleotide-binding domain and leucine-rich repeat-containing receptors (NLRs) (Table 4). 
Intracellular RLRs act as sensors during viral replication by recognizing double-stranded RNA 
(dsRNA) from dsRNA viruses or from the replication intermediate of single-stranded RNA 
viruses. Upon ligand binding, RLRs can activate the expression of type I IFN and inflammatory 
cytokines [111]. NLRs are composed of two major families, including nucleotide-binding 
oligomerization domain (NOD) receptors and NLRP family (NLRP1-14). NOD1 and NOD2 
recognize the components of bacterial peptidoglycan, such as mesodiaminopimelic acid and 
muramyl dipeptide, respectively, which lead to transcriptional activation of proinflammatory 
cytokine via NF-κB pathway [112]. Other NLRs involve in the formation of the inflammasome 
and mediate caspase-activation and IL-1 secretion [113].  
 
(3) Transmembraneous PRRs include C-type lectin receptors (CLRs) and Toll-like receptors 
(TLRs). CLRs recognize microbial surface carbohydrates in a calcium-dependent manner. For 
instance, dectin-1 and dectin-2 are transmembrane proteins of CLRs with an extracellular 
carbohydrate recognition domain (CRD) and immunoreceptor tyrosine-based activation 
motif (ITAM)-like intracellular tail [114]. Dectin-1 and dectin-2 which expressed by DCs, 
macrophages, and neutrophils, are responsible for sensing β-glucans and α-mannan from 
fungi, respectively [115-116]. Upon ligand binding, SH2 domain-containing tyrosine kinases 
are recruited to ITAM, following by transcriptional activation of cytokines genes such as IL-1β, 
IL-12 and IL-23 in response to fungal infection. 
 
TLRs compose the major groups of transmembrane PRRs. TLRs are induced or constitutively 
expressed throughout the GI tract by a variety of cells, including IEC lineages, DCs, and 
macrophages. To date, thirteen TLRs have been identified in mammals, but only ten have 
been reported in human. Based on the ligand recognition sites, TLRs are localized either at 
the cell surface or in intracellular (endosomal/lysosomal) compartment (Table 4). TLRs 
consist of extracellular leucine-rich repeats (LRRs) involved in ligand binding, a 
transmembrane domain, and a cytoplasmic Toll/IL-1R homology (TIR) domain involved in 
intracellular signaling [108]. The TLRs signaling pathways are depicted in Figure 5. 
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Table 4. Pattern recognition receptors and their microbial ligands (Adapted from [104, 108]) 
TLR Localization Ligand Origin of the ligand 
TLR1 Plasma membrane Triacyl lipoprotein Bacteria and mycobacteria 
TLR2 Plasma membrane Lipoprotein  
peptidoglycan 
Phospholipomannan 
Zymosan 
Bacteria and mycobacteria 
Gram-positive bacteria 
Fungi 
Yeast 
TLR3 Endolysosome dsRNA Viruses 
TLR4 Plasma membrane LPS 
Mannan 
Envelope proteins 
Gram-negative bacteria 
Fungi (Candida spp.) 
Viruses 
TLR5 Plasma membrane Flagellin Flagellated bacteria 
TLR6 Plasma membrane Diacyl lipoprotein 
Lipoteichoic acid 
Zymosan 
Mycobacteria 
Gram-positive bacteria 
Fungi 
TLR7/8 Endolysosome ssRNA RNA Viruses 
TLR9 Endolysosome CpG-DNA (unmethylated) 
DNA 
Hemozoin 
Bacteria  
Viruses 
Protozoa (Plasmodium) 
TLR10 Plasma membrane Unknown Unknown 
TLR11/12 Endolysosome Profilin-like molecule Protozoa (Toxoplasma) 
TLR13 Endolysosome 23S rRNA Bacteria 
RLR    
RIG-1 Cytoplasm dsRNA (5’ triphosphate) RNA viruses, DNA viruses 
MDA5 Cytoplasm Long dsRNA RNA viruses 
NLR    
NOD-1 Cytoplasm Peptidoglycan (iE-DAP) Bacteria 
NOD-2 Cytoplasm Peptidoglycan (MDP) Bacteria 
CLR    
Dectin-1 Plasma membrane β -glucan Fungi 
Dectin-2 Plasma membrane β –glucan and α-mannan Fungi 
MDA5, Melanoma differentiation-associated gene 5; MDP, muramyl dipeptide; iE-DAP, 
g-D-glutamyl-mesodiaminopimelic acid;  
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TLR signaling is essential to initiate the innate immune response against pathogens. 
Consequently, a defective TLRs signaling is associated with various diseases. For instance, 
TLR5-deficient mice develop spontaneous colitis [117]. TLR2- and TL4-deficient mice are 
susceptible to bacterial infections [118], and TLR11-deficient mice are susceptible to 
intracellular parasite infection [119]. Moreover, aberrant activation of TLRs is also involved in 
the pathogenesis of autoimmune and chronic inflammatory diseases [120]. To limit 
inappropriate immune activation to commensal bacteria, TLR signaling is tightly regulated by 
restricted expression patterns or functional compartmentalization. For instance, bone 
marrow-derived DCs express high levels of TLR4 to rapidly recognize detrimental threats in 
the blood circulation, whereas LP-derived DCs express low levels of TLR4 to avoid 
hyper-responsiveness against widespread LPS in the gut lumen [121]. TLR5, the receptor for 
bacterial flagellin, is mainly localized at the basolateral surface of IECs. This expression 
pattern ensures that immune activation only occurs during bacterial invasion as a result of 
impaired epithelial junctions, but not over activates at the apical mucosal surface. 
 
Additional mechanisms that negatively regulate TLR signaling, include soluble decoy 
receptors, intracellular and membrane-bound inhibitors [122]. Soluble decoy TLRs (sTLR2 and 
sTLR4) function as antagonists, and prevent over-activation of TLR signaling [25, 123]. 
Intracellular regulators like suppressor of cytokine signaling 1 (SOCS1) and IL-1 
receptor-associated kinase-M (IRAKM) down-regulate TLR signaling through inhibition of 
IRAK-TRAF6 complex [124-125]. Membrane-bound inhibitors include ST2, single 
immunoglobulin IL-1-related receptor (SIGIRR), and TNF-related apoptosis-inducing ligand 
receptor (TRAILR). ST2 inhibit TLR signaling by sequestration of the adaptor MyD88 and MAL 
proteins [126]. SIGIRR binds to TLR4 and IRAK and suppresses downstream signaling [127], 
whereas TRAILR suppress NF-κB activation in both MyD88-dependent and independent 
pathways [128]. Overall, negative regulation is required to balance immune responses, since 
defects of negative regulators are associated with autoimmune, chronic inflammatory and 
infectious disease [122, 129]. 
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Figure 5. Toll-like receptor signaling pathways (Adapted from [122, 130]). TLRs signaling is initiated 
by ligand-induced dimerization of receptors, either in plasma membrane or endosome, followed by 
activation of MyD88-dependent or TRIF-dependent pathway. Engagement of adaptor proteins to TIR 
domain activates IRAKs and the adaptor molecules TNF receptor-associated factors (TRAFs), and lead 
to transcriptional factors such as NF-κB and IRF3. Hence, the transcriptional activation leads to the 
expression of pro-inflammatory cytokines or Type I IFN. IRAK, IL-1R associated kinase; IRF, 
Interferon-regulatory factor; IKK, inhibitor of NF-κB; MAPK, mitogen-activated protein kinase; TRAILR, 
TNF-related apoptosis-inducing ligand receptor; TAB, TAK-1 binding protein; TAK, TGFβ-activated 
kinase; MyD88, myeloid differentiation primary response protein 88. 
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2.5 Adaptive immunity  
 
The efficient clearance of pathogens and induction of tolerance to commensal bacteria at 
intestinal mucosa requires the coordination of innate and adaptive immune system. Upon 
antigenic stimulation, innate immunity triggers the activation of adaptive immunity. In 
contrast to innate immunity, adaptive immunity confers highly specific and long-lasting 
immunity. Adaptive immune cells consist of a repertoire of T and B lymphocytes, whose 
differentiation is coordinated by antigen-presenting cells (APCs), cytokines, and other 
environmental factors. APCs play a critical role in the crosstalk between innate and adaptive 
immune responses.  
 
Naive T cells are divided into CD4
+
 T-helper (TH) cells and CD8
+
 cytotoxic T cells (CTLs). TH cells 
are activated through the binding of antigens presented on MHC-II by APCs, whereas CTLs 
are activated through MHC-I found on most nucleated cells. Upon activation, TH cells respond 
to various cytokine-signals and differentiate into several subtypes, such as TH1, TH2, and TH17 
cells, which promote inflammation and clearance of pathogens, or regulatory T cells (TReg or 
TR1), which mediate immunosuppression. The differentiation of intestinal CD4
+
 T cells are 
summarized in Figure 6.  
 
TH cells are characterized by the production of distinct cytokines and the expression of 
lineage-specific transcription factors. TH1 cells elicit cell-mediated immunity and 
inflammation against mainly intracellular bacterial and viral antigens. Upon antigenic 
stimulation, naive T cells primed in the presence of IL-12, differentiate into TH1 cells and 
induce the production of cytokines such as IL-2, IFN-γ, and TNF-α. TH1 cytokines enable the 
activation and recruitment of macrophages, NK cells, and CTLs to the site of infection. By 
contrast, TH2 cells are involved in humoral-mediated immunity against the extracellular 
parasites. After activation in the presence IL-4, naive T cells differentiate into TH2 cells, and 
secrete themselves IL-4, IL-5, and IL-13. Consequently, the induction of TH2 cytokines triggers 
the production of IgE from B cells and promote eosinophils-mediated inflammation against 
the extracellular parasites. Notably, key cytokines (e.g. IFN-γ, IL-4) produced from TH1 and 
TH2 cells, and lineage-specific transcription factors (e.g. T-bet, GATA-3) provide positive 
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feedback mechanisms to maintain self-differentiation, but also mutually inhibit each others 
to reinforce their lineage fate.   
 
 
 
Figure 6. Differentiation of intestinal CD4
+
 T cells (adapted from [131-132]). Differentiation of TH cell 
subsets from naive T cells is induced upon interaction with the antigen associated MHC-II and 
co-stimulatory signal by antigen presenting cells. TH cells can differentiate into effector T cells (TH1, 
TH2, TH17) that promote inflammation and clearance of pathogens, or regulatory T cells (TReg, TR1, and 
Th3) that suppress immune response. Differentiation of TH cells is mediated by cytokine-induced 
signals (such as IL-4, IL-6, IL-10, IL-12, and TGF-β) and the expression of transcription factors (T-bet, 
GATA-3, RORγt and FOXP3). CTL, cytotoxic T cells; MФ, macrophage; NK, natural killer; RA, retinoic 
acid; T-bet, T-box transcription factor; GATA3, GATA-binding protein 3; RORγt, RAR-related orphan 
receptor γ; FOXP3, Forkhead box P3.  
 
 
INTRODUCTION 
 
35 
 
The discovery of TH17 cells has opened a new concept to the TH1/ TH2 paradigm of adaptive 
immunity. TH17 cells exhibit distinct effector functions than TH1 and TH2 cells, mediating the 
clearance of extracellular pathogens like bacteria and fungi. Upon antigenic stimulation, TH17 
cells, activated by IL-6 and IL-23, are responsible for producing IL-17A and IL17F which 
promotes neutrophil chemotaxis and pathogen elimination. TH17 cells can also produce IL-22, 
which contributes to maintaining the epithelial barrier by enhancing the secretion of 
antimicrobial proteins and mucins from IECs [133]. Defects in TH17 cell functions increase 
susceptibility to commensal fungal infections, as shown by the reduction of IL-22 and 
neutrophils recruitment in both TH17 (Il23p19
-/-
) and IL-17R (Il17r
-/-
) deficient mice, 
demonstrating the importance of TH17 mediated anti-fungal response in mucosal immunity 
[134]. However, aberrant regulation of TH17 also leads to chronic intestinal inflammation 
[135-136] and contributes to the emergence of autoimmune diseases [137-138]. 
 
The balance between immune activation and immune tolerance is controlled by a specialized 
T cell subset, known as TReg. The differentiation of functional TReg is activated by retinoic acid, 
TGF-β and lineage-specific transcription factor forkhead box P3 (FOXP3). Deficiency in FOXP3 
is associated with massive lymphocytes proliferative disease [139]. FOXP3
+
-TReg cells produce 
large amounts of TGF-β, IL-10, and IL-35 which suppress the expansion of effector TH1 and 
TH17 cells, and also block the activation of macrophages and NK cells in the intestine [140].  
 
The critical roles of TReg in mediating immunosuppression are manifested by the secretion of 
anti-inflammatory cytokines, such as IL-10 and TGF-β. These cytokines are essential for 
intestinal homeostasis as shown by the spontaneous intestinal inflammation characterizing 
mice deficient of IL-10 and TGF-β [141-142]. Moreover, mutations of IL-10 receptor are also 
associated with inflammatory bowel disease in human [143]. Apart from natural TReg, 
another subset of regulatory T cells, known as TR1 and Th3 cells, can be induced in the 
periphery. These cells are important in maintaining immune-tolerance mainly through the 
production of high level of IL-10 and TGF-β, respectively [144]. Along with T-cell mediated 
immunity, the humoral response induced by B-cells contributes to protecting the host from 
pathogenic infections. The activation of B cells is mainly driven by TH2-cytokines, such as IL-4 
and IL-5, but can also be induced by DC-driven responses. Upon antigenic stimulation, 
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mucosal B cells differentiate into plasma B cells and secrete IgA. IgA is the most abundant 
immunoglobulin isotype in the intestinal mucosa. Secretory IgA is transported through the 
epithelial layer (transcytosis) to the intestinal lumen and opsonized bacteria or toxins to 
restrict their attachment and penetration of the gut epithelial layer [145]. In addition, study 
on IgA-deficient mice suggested the importance of sIgA to block virus entry into Peyer’s 
patches [146]. TGF-β signaling is also essential for the induction of IgA [147]. Besides the 
prevention of pathogenic infection, sIgA also exhibits anti-inflammatory effects, contributing 
to the mucosal homeostasis. 
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3. Gut microbiota and immune system 
 
The human GI tract is colonized by large numbers of diverse microorganisms, including fungi, 
parasites, virus, and mostly bacteria, which is collectively referred to as the gut microbiota. 
The heterogeneous microenvironment in the gut influences the abundance, diversity, and 
distribution of the gut microbiota through the GI tract. Bacterial numbers can range from 
10
2
-10
3
 per gram luminal contents in gastric-duodenal region to 10
11
-10
12
/g predominantly 
anaerobic bacteria in the caecum and distal colon [148]. It is generally accepted that the 
intestinal microbiota comprises more than 1000 different bacterial species [149], however 
only a small minority can be cultured. Recently, advances in culture-independent sequencing 
have greatly improved our understanding to a variety of microbes and enabling the rapid 
detection of spatial, temporal, and compositional changes in our microbiota. In human, the 
dominant gut bacterial species belong to two major phyla, Firmicutes and Bacteroidetes 
(>90%) whereas Actinobacteria, Proteobacteria Cyanobacteria, Fusobacteria and 
Verrucomicrobia present in relatively low abundance [150]. Moreover, a comprehensive 
study of global gut microbiota has categorized the human microbiota into three predominant 
enterotypes (Bacteroides, Prevotella, or Ruminococcus) as driven by dietary intake [151].  
 
3.1 Contributions of the gut microbiota 
 
The colonization of the GI tract by commensal microbiota leads to a mutualistic relationship 
between host and microbiota. The investigation on germ-free (GF) mice outlines the multiple 
roles of microbiota in the host physiology including metabolic, protective, and structural 
functions (Figure 7). The gut microbiota supports normal metabolic functions of the host by 
degradation of non-digestible substances, production of short-chain fatty acids (SCFAs) and 
essential vitamins, and absorption of ion. This is evidenced in GF animals, which require a 
higher caloric intake [152], and are prone to vitamin deficiencies [153] compared to 
conventionally reared animals. It is also known that microbiota is pivotal in regulating 
intestinal morphology, as shown in GF animals which have aberrant crypt and villus [154], 
impaired IECs proliferation and reduced epithelial tight junctions [155]. Notably, GF animals 
are more susceptible to infection due to multiple defects in the mucosal immunity. These 
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include a reduced size of MLNs and Peyer’s patch follicles [156], decreased plasma cells and 
IgA production [157], decreased Paneth cells and antimicrobial proteins [158], and decreased 
isolated lymphoid follicles [159]. However, reconstitution of commensal bacteria is sufficient 
to provide protection against infections implying that gut microbiota is critical to restore the 
intestinal barrier and mucosal immunity [160-162]. Moreover, components derived from 
commensal bacteria such as LPS and polysaccharide A (PSA) can also affect the normal 
development of mucosal immunity [163]. 
 
 
 
Figure 7. Functions of the intestinal microbiota (adapted from [154, 164]). Commensal bacteria 
display multiple biological functions on the intestinal mucosa of the host. 
 
3.2 Gut microbiota and IBD 
 
The composition of the human gut microbiota is highly dynamic at the infant stage. During 
infancy, external factors, such as delivery mode and feeding, initially influence the 
colonization of gut microbiota. As the infant grows, diet, environmental and genetic factors 
progressively shape the gut microbiota and toward a relatively stable microbial community in 
adult. Attempts to characterize the bacterial shift between healthy and disease state provide 
us a first picture to predict the disease progression and to develop relevant therapies. The 
imbalance of microbiota composition is referred to as dysbiosis, and has been associated 
with various disorders such as allergy, autism, obesity, diabetes, inflammatory bowel disease 
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(IBD), and cancer [165]. The impact of the microbiota on human health is well characterized 
by studies on IBD. IBD is primarily associated with the degree of industrialization, as 
observed from the highest incidence rate in Europe and North America. The major clinical 
forms of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). Both are chronic and 
relapsing inflammatory disorders of the gastrointestinal tract. Of which, CD affects the entire 
GI tract and is characterized by transmural inflammation with large ulcerations and 
granulomas formation, whereas, UC mainly affects on colon and rectum with superficial 
ulceration and crypt abscesses [166]. Although the exact etiology of IBD remains unclear, it is 
generally hypothesized that the disease developed in genetically predisposed individual who 
has overactive immune responses against the commensal bacteria [167]. Recently, 
genome-wide association studies have been successfully identified genetic variants that 
contribute to IBD susceptibility [168-169]. Despite distinct clinical patterns, approximately 
30% of IBD-related genetic abnormalities are shared between CD and UC [170], and are 
categorized into epithelial barrier functions (CDH1, HNF4a, PTPN2), innate sensors 
recognition (NOD2, CARD9, TLR4), immune cells regulation (STAT3, IL-2, IL-10, IL-23R), ER 
stress (XBP1) and autophagy (ATG16L1) (Figure 8). 
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Figure 8. Development and pathogenesis of IBD (adapted from [171]). Host genetic and 
environmental factors influence the microbial homeostasis in the intestine mucosa. In homeostasis, 
commensal bacteria trigger tolerogenic DCs and the development of regulatory T cells. The 
development of IBD is frequently initiated by the altered barrier function, translocation of bacteria 
into tissue, and subsequent immune activation in genetically susceptible individuals. Failure of 
immune regulation further leads to chronic inflammation, dysbiosis and irreversible tissue damage 
which are driven by cytokine responses. 
 
The first identified gene correlating with human IBD was NOD2. NOD2 is an innate receptor, 
which recognizes bacterially derived muramyl dipeptide and triggers both innate and 
adaptive immune responses. Studies based on Nod2-deficient mice and CD-associated Nod2 
mutations in human suggest the defects of such innate sensor results in decreasing defensins 
production by Paneth cells, and reducing proinflammatory cytokines production (IL-1β, 
TNF-α, IL-6 and IL-23) by antigen-presenting cells. Other families of innate receptors such as 
NLRs and RLRs also associated with innate defense, as evidenced by an increased 
susceptibility to colitis in NLRP3 or RIG-I deficient mice [172-173]. Adaptor protein like 
CARD9 (Caspase recruitment domain-containing protein 9) integrates the signals from innate 
receptors to downstream NF-κB signaling is also implicated in IBD [174]. In addition to innate 
defense, genes associated with epithelial tight junction including CDH1 (E-cadherin) and 
PTPN2 (protein tyrosine phosphatase) are critical in maintaining intestinal barrier, also 
implicated in human IBD [175-176]. Moreover, mutations in the autophagy regulatory genes 
(ATG16L1) and immunity-related GTPase family M (IRGM) are also observed in CD patients 
due to abnormalities of Paneth cell and defects in bacterial clearance [177-178]. 
 
The onset and relapse of IBD are also associated with environmental factors which affect the 
intestinal mucosa barrier or immune responses. These factors include hygiene, diet, 
medication, infection, stress, and smoking [179]. However, how these factors initiate or 
reactivate the disease remain poorly understood. Medication such as antibiotics and 
nonsteroidal anti-inflammatory drugs (NSAIDs) influence mucosal barrier and mediate 
non-specific inflammation, as evidenced by a significant correlation between antibiotic use 
and CD [180], as well as NSAIDs-induced colonic ulcerations [181]. Stress is also implicated in 
the intestinal inflammation due to an increasing epithelial permeability and mucosa damage 
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in animal models [182-183]. Notably, smoking is well implicated in IBD pathogenesis, 
however, plays a paradoxical role in CD and UC patients. A meta-analysis has suggested that 
active smokers increase the risk of developing CD but decrease the risk of developing UC 
compared to non-smokers [184]. The impact of diet on IBD has also been extensively studies. 
A systemic review has suggested that high dietary intakes of total fats and PUFAs are positive 
correlated with an increased risk of both CD and UC [185]. 
 
3.3 Pathogenic role of gut microbiota in IBD  
 
Alteration of microbiota composition has long been observed in human IBD and 
experimental colitis. Numerous studies have indicated a potential pathogenic role of gut 
microbiota in the progression of the disease, as evidenced by amelioration of colitis in 
antibiotic-treated and GF animals. Commensal bacteria are critical to maintain the gut 
homeostasis and symbiotic relationship between the host. However, some bacteria can 
acquire pathogenic features under abnormal conditions, such as acute inflammation and 
dysregulation of the immune system. These bacteria are collectively referred to as 
pathobionts, such as E. coli, Enterococcus faecalis, Bacteroides vulgatus, Prevotella and 
Klebsiella species which have all been shown to induce colitis in genetic predisposed mouse 
[186] (Table 5). The colitogenic property of pathobionts nevertheless depends on the host 
specific immune defects, as evidenced for B. vulgatus that triggers colitis in Il10r2
-/-
 and 
Tgfbr2
-/-
 mice but not in Il2
-/-
 or Il10
-/-
 mice [187-188]. On the other hand, E. coli induces 
colitis in germ-free Il10
-/-
 mice but not in Il10r2
-/-
 and Tgfbr2
-/-
 mice [187, 189].  
 
Meta-analysis of microbial diversity has frequently observed an expansion of Proteobacteria 
in patients with IBD. In particular, increasing numbers of adherent invasive E. coli (AIEC) [190], 
Campylobacter, Salmonella and Helicobacter spp. have all been observed in patients with IBD 
(Table 5). The mechanism by which AIEC induce colitis is associated with their invasiveness 
and potential to drive inflammatory responses. AIEC invades and survives within macrophage 
phagolysosome without inducing cell death, allowing them to continuously proliferate and 
trigger TNF-α release which then drives chronic inflammation [191]. AIEC has also been 
reported to induce the aggregation of infected macrophages and lymphocytes to form 
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granulomas, a clinical feature in CD patients [192]. Taken together, these virulence-like 
factors highlight the causative role of AIEC in the development of IBD.  
 
Table 5. Gut microbiota associated with IBD pathogenesis (Adapted from [186, 193]). 
Bacteria species Host type Disease model Potential mechanisms 
Adherent-invasive  
E. coli (AIEC) 
Human CD Increased prevalence in patients, 
induce granulomas, increase TNF 
Salmonella spp. Human UC and CD Previous infection predisposes to IBD 
Campylobacter jejuni Human UC and CD Previous infection predisposes to IBD 
Campylobacter concisus  Human UC and CD Increased IL-8 and TNF activation  
Helicobacterspp. 
(Enterohepatic) 
Il10
-/- 
Mouse Spontaneous 
colitis 
Induced colitis in Il10
-/- 
mice 
Klebsiella spp.  
 
Mouse TNBS-induced 
colitis 
Increased IL-1β, IL-6 and TNF-α 
activation 
Prevotellaceae  
TM7  
Nlrp6
-/-
, Asc
-/-
 or 
Casp1
-/-
 Mouse 
DSS-induced 
colitis 
Impaired IL-18 signaling promotes 
pathobiont expansion  
B. vulgatus  
B. thetaiotaomicron   
Il10r2 
-/-  
Mouse 
Tgfbr2 
-/- 
Mouse 
Spontaneous 
colitis 
Colonization of antibiotic-treated mice 
triggers colitis  
Escherichia coli 
 
Il2 
-/-  
Mouse 
Il10 
-/- 
Mouse 
Spontaneous 
colitis 
Monocolonization of GF mice induces 
colitis  
Enterococcus faecalis  Il10 
-/- 
Mouse Spontaneous 
colitis 
Monocolonization of GF mice induces 
colitis  
DSS, dextan-sulfate sodium ; TNBS, 2,4,6-trinitrobenzene sulphonic acid; Il2, interleukin 2; Il10, 
interleukin 10; Nlrp6, NOD-, LRR- and pyrin domain containing 6 ; Casp1, caspase 1; Asc, 
apoptosis-associated speck-like protein containing-CARD; Tgfbr2, transforming growth factor beta 
receptor 2; TNF, tumor necrosis factor;  
 
Increasing evidences also demonstrated that previous infection with a class of 
Campylobacter, Salmonella, or Helicobacter species increase the risk of the host to develop 
IBD [194]. For example, exposure of C. jejuni to host has been shown to induce murine colitis 
[195] and highly correlated with human IBD [196]. A high prevalence of Campylobacter 
concisus is also observed in IBD patients [197-198]. Characterization of C. concisus strain has 
revealed its ability to secrete cytolethal toxins and to induce inflammatory response. Studies 
have also shown that infection with Helicobacter hepaticus significantly exacerbate colitis in 
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Il10
-/-
 mice through IFN-γ and IL-12 driven over-activation of TH1 response [199]. Taken 
together, the development of IBD is associated with host specific immune factors and the 
resulting microbial dysbiosis. The proposed mechanisms by which the accumulation of these 
pathobionts influence the susceptibility of IBD are associated with bacterial toxins, breakage 
of epithelial barrier, increase of membrane permeability, and stimulation of TH1 and TH17 
inflammatory responses [200].  
 
3.4 Protective role of gut microbiota in IBD 
 
Although various pathobionts promote the development of IBD, some commensal bacteria 
also contribute to lessening the severity of IBD. The protective role of commensal bacteria is 
demonstrated in GF mice, which are more susceptible to experimental colitis than 
conventionally reared mice, whereas reconstitution of commensal bacteria decrease the 
disease [201]. The beneficial roles of these probiotics to gut mucosa of the host are 
associated with their immunomodulating activities and metabolic functions (Table 6). For 
example, reconstitution of Clostridium spp. (clusters XIVa and IV) has been shown to 
ameliorate the experimental colitis in mice through induction of FOXP3
+
-TReg cells and the 
reduction of systemic IgE response [202]. In addition, numerous Bifidobacteria and 
Lactobacillus spp. have been shown to initiate TReg cells and mediate anti-inflammatory 
response in both murine colitis model and human IBD [203-204].  
 
Commensal bacteria also exert anti-inflammatory effects through their production of SCFAs. 
SCFAs are major bacterial fermentation products, including mainly acetate, propionate, and 
butyrate. Propionate is mostly metabolized in liver while butyrate is the major energy source 
of colonocytes. The beneficial roles of SCFAs on the host have been demonstrated in IBD 
patients whose fecal SCFAs level are inversely correlated with the clinical symptoms [205].  
 
The mechanisms by which SCFAs interact with host cells involve both intracellular and 
extracellular signaling pathways. Absorption of luminal propionate and butyrate by colonic 
epithelial cells inhibits the activity of histone deacetylases, which in turn promotes the 
hyperacetylation of histone and activates the targeted gene expression [206]. Butyrate and 
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propionate increase the expression of FOXP3, thereby induce the differentiation of TReg cells 
that suppress the inflammatory response [207]. Extracellular SCFAs interact with G 
protein-coupled receptors such as GPR41 and GPR43, which are expressed on colonic 
epithelial cells and immune cells, and mediate the activation of TReg cells and the production 
of IL-10 and TGF-β [208-209]. Overall, the immunosuppressive effects of probiotics and their 
metabolic products have been evaluated for treatment of IBD. Prebiotics that selectively 
increase beneficial bacteria and SCFAs production also provide a new perspective in IBD 
therapy.  
 
Table 6. Protective roles of the gut microbiota in the IBD (Adapted from [158, 186]). 
Bacteria species Host type Disease model  Mechanism of disease suppression 
Bacteroides fragilis  Mouse  TNBS colitis  Induction of Treg and IL-10 via PSA 
Bacteroides vulgatus  Il2
-/-
 Mouse Spontaneous colitis  Suppression of inflammation 
Bifidobacteria lactis Rat TNBS-colitis Decreased levels of TNF and iNOS 
Bifidobacteria infantis Mouse Salmonella-induced 
Enteritis 
Induction of Treg  
Clostridium butyricum Rag2
-/-
 Mouse DSS-colitis Induction of Treg
 
and IL-10 
Clostridial IV and XIVa  Mouse  DSS-colitis  Induction of Treg 
E. coli Nissle 1917 Mouse 
Human 
DSS-colitis 
Ulcerative colitis 
Decreased TLR2 and TLR4 activation 
 
Faecalibacterium 
prausnitzii  
Mouse 
Human 
TNBS-colitis  
Ulcerative colitis 
Induction of IL-10, Decreased IL-8  
Induction of IL-10, Butyrate 
Lactobacillus casei Rat TNBS-colitis Decreased levels of cyclooxygenase2  
Lactobacillus reuteri Il10 
-/- 
Mouse Spontaneous colitis Decreased levels of TNF and IL-8 
DSS, dextan-sulfate sodium ; TNBS, 2,4,6-trinitrobenzene sulphonic acid; Il2, interleukin 2; Il10, 
interleukin 10; Rag2, recombination-activating gene2; PSA, polysaccharide A; TNF, tumor necrosis 
factor; iNOS, inducible nitric oxide synthase, Treg, regulatory T cells;  
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4. Glycosylation and immune system 
 
Glycosylation is a key posttranslational modifications of proteins and lipids. Glycosylation 
occurs mainly in the lumen of the endoplasmic reticulum and Golgi apparatus [210]. Glycans 
are the fundamental macromolecules of the cells together with nucleic acids, proteins, and 
lipids. In contrast to the linear macromolecules (DNA and proteins), glycans display complex 
branched structures, and no template controls their biosynthesis. The diversity of glycans on 
glycoconjugates is derived from a stepwise combination of glycosyltransferases and 
glycosidases in response to genetic and environmental stimuli. Glycosylation contributes to a 
variety of biological functions including regulation of protein folding and secretion, structural 
stability, cellular development, receptor binding and activation [211]. Moreover, the 
structural diversity and unique signature of glycans among organisms allow cells to 
distinguish them from non-self components, therefore contribute to the immune tolerance 
and activation. 
 
4.1 Sialylation  
 
Sialic acids are nine-carbon keto-containing monosaccharides, widely expressed as terminal 
glycans on glycoconjugates of eukaryotic and some prokaryotic cells. The sialic acid family 
consists of over 60 naturally occurring monosaccharides which are derived from the core 
structure N-acetylneuraminic acid (Neu5Ac). The common modification of sialic acid is found 
at C-5 position and is replaced by a N-glycolyl group (Neu5Gc), a hydroxyl group 
(2-keto-3-deoxynonoic acid, KDN), and less commonly a 5-amino group (Neu). Additional 
modifications include substitution of the hydroxyl group on C-4, C-7, C-8, and C-9 positions to 
acetyl-, methyl-, sulfate-, lactyl- and phosphate groups all contribute to the diversity of sialic 
acid [212] (Figure 9).  
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Figure 9. The diversity of sialic acids (Adapted from [212]). The diversity of sialic acids arises from a 
variety of modifications, The common modifications are identified at C-5 position, such as N-acetyl 
group (Neu5Ac), N-glycolyl group (Neu5Gc) or hydroxyl group (KDN), and less commonly 5-amino 
group (Neu). The hydroxyl group at C-4, C-7, C-8, and C-9 positions can be also modified by O-methyl, 
O-acetyl, O-lactyl, O-sulfate and O-phosphate group. 
 
Sialylation is critical for a variety of cellular functions. The biosynthesis of sialic acid in the 
cytosol is catalyzed by a bifunctional enzyme UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE) 
which converts UDP-GlcNAc into ManNAc-6-phosphate. Mutation on Gne is embryonic lethal 
in mice, suggesting the essential role of sialylation during development [213]. 
ManNAc-6-phosphate is further converted to Neu5Ac and transported into the nucleus 
where CMP-Neu5Ac synthase (CMAS) formed CMP-Neu5Ac. The nucleotide activated sugar, 
CMP-Neu5Ac, is then imported into the Golgi compartment, where the sialylation of 
glycoconjugates is catalyzed by a group of 20 sialyltransferases. The metabolism of sialic acid 
and sialoconjugates is summarized in Figure 10. 
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Figure 10. Metabolism of sialic acid (Adapted from [214]). The biosynthesis of sialic acid begins with 
the conversion of UDP-GlcNAc to N-acetylmannosamine (ManNAc) followed by phosphorylation to 
ManNAc-6-phosphate by the bifunctional enzyme UDP-GlcNAc-2-epimerase/ManNAc kinase (Gne). 
ManNAc-6-phosphate is then converted to Neu5Ac-9-phosphate and followed by dephosphorylation 
into Neu5Ac. Neu5Ac is activated by CMP-Neu5Ac synthase (CMAS) to form CMP-Neu5Ac in the 
nucleus. CMP-Neu5Ac is then imported via a specific transporter (SLC35A1) into the lumen of the 
Golgi apparatus where the synthesis of sialoconjugates is catalyzed by a variety of sialyltransferases. 
The breakdown of sialoconjugates is mediated by sialidases (Neu1, Neu4) in lysosome or (Neu2 and 
Neu3) in the cytosol. 
 
To date, twenty sialyltransferases are identified in mammals and characterized into four 
families (i.e. St3gal, St6gal, St6galnac, and St8Sia) based on their linkage and substrate 
specificity. The known substrates and the biological roles of sialyltransferases are 
summarized in Table 7. 
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4.2 Sialylation and sialyltransferases 
 
The St3gal family contains six sialyltransferases (St3gal1- St3gal6) which transfer sialic acid in 
α2,3 linkage to Gal. St3gal1 regulates CD8
+
 T cell apoptosis and promotes the formation of 
CD8
+
 T cell memory [215]. St3gal3 mediates eosinophil apoptosis via synthesis of siglec-F 
ligand, as evidenced by an increasing allergic eosinophilic response in St3gal3
 
deficient mice 
[216]. St3gal4 and St3gal6 are both involved in the synthesis of the selectin ligand sialyl 
Lewis X (sLe
x
), which plays a critical role in leukocyte trafficking, as evidenced by impaired 
neutrophil recruitment and lymphocyte homing in double-deficient mice [217-218]. 
Moreover, St3gal4 is also responsible for synthesizing milk α2,3-sialyllactose, which affects 
the colonization of gut microbiota and the susceptibility of mice to experimental colitis [219]. 
St3gal5 is mainly expressed in the neural tissues and catalyzes the first step of ganglioside 
GM3 synthesis. Mutation in St3gal5 leads to a neurological disorder characterized by 
recurrent seizures and intellectual disability [220].   
 
Two sialyltransferases St6gal1-2 and six sialyltransferases St6galnac1-6 transfer sialic acid in 
α2,6 linkage on Gal and GalNAc acceptors, respectively. St6gal1 mediates the synthesis of 
the siglec-2 ligand (CD22), which modulates the B cell receptor activation [221], while 
St6gal2 expression is restricted to the brain, suggesting its potential function in neuronal 
development [222]. The biological functions of the St6galnac family are less understood. 
Most of these sialyltransferases mediate the sialylation on O-GalNAc glycans, and glycolipids, 
suggesting their potential roles in regulating cellular adhesion and signaling [223]. 
 
Finally, the St8Sia family contains six sialyltransferases (St8Sia1-6), which elongate sialic acid 
in α2,8 linkage and form polysialic acid chains. In mammals, the presence of polysialic acid is 
restricted to a small number of glycoproteins and gangliosides [223]. The best-characterized 
poly-sialylated glycoprotein is neural cell adhesion molecule (NCAM). NCAM mediates 
adhesive property and neural plasticity of cells through the intermolecular repulsion 
generated from negatively charged-polysialic acid chains [224]. Recently, St8Sia2 and St8Sia4 
have also been associated with the polysialylation on the synaptic cell adhesion molecule 
(SynCAM1) in the brain [225].  
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Table 7. Summary of human sialyltransferase family (Adapted from [223, 226]). 
 
 
4.3 Sialylation and microorganisms  
 
Mucosal surface is covered with a thick layer of mucus that contains a multitude of glycan 
epitopes. Given the abundance of sialic acids as the outermost carbohydrates on cell 
membranes, numerous bacteria and viruses utilize host-derived sialylated glycans as 
receptors for adhesion and infection. Recently, several sialic acid-binding agglutinins, 
α3
β3/4
α3 β3
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adhesins, and lectins have been identified in microbes, and many are considered as virulence 
factors for infection. For instance, Vibrio cholerae, H. pylori, E. coli enterotoxin, 
and botulinum toxin target specific mucosal sialylated glycans [227-229]. Moreover, bacteria 
such as commensal Bifidobacteria and Bacteroides spp. secrete sialidases and hydrolyze 
host-derived sialylated glycans for nutritional purposes. Besides using sialidases for nutrient 
acquisition, several pathogens also exploit sialidases to unmask underlying host ligands for 
further adherence and infection. For instance, C. perfringens and V. cholera sialidases are 
critical virulence factors, which reveal underlying cryptic ligands as binding sites for epsilon 
toxin and cholera toxin, respectively [230-231]. The sialidase-producing bacteria and 
substrate specificity are summarized in Table 8. 
 
Table 8. Sialidase-producing bacteria and substrate specificity (Adapted from [232-233]). 
Mucosal site Sialidase-producing bacteria Substrate  
Gastrointestinal 
tract 
Bacteroides fragilis 3SL, 6SL, LST, GM1, fetuin, mucin 
Bacteroides thetaiotaomicron HMO sialyllactose, mucin 
Bacteroides vulgatus HMO sialyllactose, mucin 
Bifdobacterium longum HMO sialyllactose 
Bifdobacterium infantis HMO sialyllactose 
Clostridium perfringens 3SL, 6SL, GM1, mucin 
Salmonella typhimurium 3SL, 6SL, colominic acid, fetuin, mucin 
Vibrio cholerae Ganglioside GM1, GM2, GM3, GD1 
  
Buccal cavity Porphrymonas gingivalis Sialyllactose, α1-acid glycoprotein 
Tannerella forsythia 3SL, 6SL, colominic acid, fetuin, mucin 
  
Respiratory tract Haemophilus influenzae Uncharacterized sialic acid scavenge  
Streptococcus pneumoniae 3SL, 6SL, IgA1, lactoferrin,  
Pasteurella multocida 3SL, 6SL, GM1, GD1a, colominic acid 
Pseudomonas aeruginosa Synthetic MU-Neu5Ac 
  
Reproductive tract Consortia in bacterial vaginosis IgA, mucins 
Gardnerella vaginalis Synthetic MU-α-Neu5Ac 
 
LST, Sialyl-lacto-N-tetrarose; MU-Neu5Ac, 2’-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid 
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Notably, bacteria such as E. coli do not express sialidase genes but are capable of scavenging 
free sialic acid as an energy source from the environment. Other bacteria such as B. 
thetaiotaomicron express sialidases but do not encode a sialic acid lyase gene (NanA), which 
is required for the initial step of sialic acid catabolism. This finding suggests that B. 
thetaiotaomicron may utilize the sialidase activity to unmask and access the underlying 
glycan structures. Such a Bacteroides-derived sialidase activity has recently been 
demonstrated to promote the proliferation of the enteropathogens Salmonella typhimurium 
and Clostridium difficile [234]. 
 
In addition to their nutritional contributions, sialic acids can be incorporated into microbial 
surface glycans, and thereby mediate the formation of self-associated molecular patterns 
(SAMPs). Recognition of SAMPs by host serum protein factor H and members of the siglec 
family dampens the activation of the complement system and inhibits innate immune 
responses, and thereby avoids pathogens being attacked by the host immune system. The 
best-known examples are pathogens such as E. coli K1, and Neisseria meningitidis. They can 
de novo synthesize polysialic acids and express capsular polysaccharides to avoid immune 
attack [235-236], as evidenced by the reduction of bacteremia and systemic infection in rat 
through the selective degradation of E. coli K1 capsular polysialic acids [237]. In addition, 
bacteria such as Haemophilus influenzae, lack de novo synthesis enzymes but can scavenge 
exogenous sialic acid and activate it into CMP-sialic acid for subsequent sialylation of surface 
lipooligosaccharide [238]. Interestingly, several pathogens have evolved various mechanisms  
to acquire sialic acid either by scavenging or de novo synthesis (Figure 11).  
 
Overall, sialylation has a profound impact on regulating the host immune system and 
microbial recognition. Therefore, regulation on microbial sialic acid metabolism and surface 
sialoconjugates can influence the interplay between the host cells and microorganisms.  
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Figure 11. De novo synthesis and metabolism of sialic acid in bacteria (Adapted from [239]). 
Summary of sialic acid catabolism (red) and de novo synthesis (blue) pathway. De novo synthesis of 
sialic acid begins with the conversion of UDP-GlcNAc to ManNAc by UDP-GlcNAc epimerase (NeuC), 
followed by condensation of ManNAc to Neu5Ac by sialic acid synthase (NeuB). Finally, CMP-sialic 
acid synthase (NeuA) catalyzes formation of CMP-Neu5Ac, providing an activated donor substrate for 
sialylation. NeuA: CMP-sialic acid synthase; NeuB: sialic acid synthase; NeuC, UDP-GlcNAc epimerase 
NanT: sialic acid permease; NanA: N-aceylneuraminic lyase; NanK: N-acetylmannosamine kinase; 
NanE: N-acetylmannosamine-6P epimerase; NagA: N-acetylglucosamine-6-P deacetylase; NagB: 
Glucosamine-6-P deaminase.  
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Sialidase
Sialylated glycans
Capsular polysialic acid 
NeuS
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Aim of the study 
 
Glycans derived from maternal milk, diet, and mucosa greatly influence the composition of 
intestinal microbiota and mediate gastrointestinal physiology. However, the direct 
contributions of glycans on regulating intestinal bacteria remain largely unclear. Imbalance in 
gut microbiota is frequently observed in response to environmental stress and in various 
disease conditions. Despite such well documented alterations, the mechanisms and 
consequences of dysbiosis on disease development remain elusive. Knowledge of specific 
glycans functions may be useful to develop prebiotics and targeted therapies against 
intestinal inflammation manifested by microbial dysbiosis. The aim of this study is to 
characterize the functional roles of glycans, especially sialic acid, in regulating intestinal 
bacteria and to determine their contributions to mucosal immunity.  
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Abstract 
Rapid shifts in microbial composition frequently occur during intestinal inflammation, but 
the mechanisms underlying such changes remain elusive. We here demonstrate that an 
increased caecal sialidase activity is critical in conferring a growth advantage for Escherichia 
coli during intestinal inflammation in mice. This sialidase activity originated from Bacteroides 
vulgatus, whose intestinal levels expanded after dextran-sulfate sodium administration. 
Increased sialidase activity mediates the release of sialic acid from intestinal tissue, which 
promotes the outgrowth of E. coli during inflammation. The outburst of E. coli exacerbated 
the inflammatory response by stimulating the production of pro-inflammatory cytokines by 
intestinal dendritic cells. Oral administration of a sialidase inhibitor and low levels of 
intestinal α2,3-linked sialic acid decreases E. coli outgrowth and the severity of colitis in mice. 
Regulation on sialic acid catabolism opens new perspectives for the treatment of intestinal 
inflammation as manifested by E. coli dysbiosis. 
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Introduction 
The intestinal microbiota has emerged as a key player in the regulation of physiological 
pathways and in the development of diseases. Along with intestinal diseases, such as 
necrotizing enterocolitis
1
 and inflammatory bowel disease
2
, gut microbiota contribute among 
others to the etiology of diabetes
3
, asthma
4
, autoimmunity
5
, and cancer
6
. Accordingly, much 
effort has been dedicated to understanding the factors influencing the composition of the 
intestinal microbiota to maintain or restore health in the host organism. 
 
Carbohydrates are a major class of food products that profoundly affect the gut microbiota. 
Whereas most monosaccharides are absorbed by the small intestine, oligo- and 
polysaccharides are not digested in the upper gastrointestinal tract and reach the colon 
intact. The impact of complex carbohydrates on microbial composition is based on the 
expression of specific hydrolases
7
, which enable some bacterial species to process and utilize 
breakdown products as nutrients, thereby conferring a proliferative advantage over bacteria 
that cannot process complex carbohydrates
8
. The first carbohydrates ingested just after birth 
are provided by breast milk, which is a rich source of lactose and oligosaccharides
9
. The 
uptake of milk oligosaccharides coincides with the microbial colonization of the gut and 
favors the proliferation of bacteria equipped with carbohydrate processing enzymes, such as 
Bifidobacterium and Bacteroides spp that are enriched in breast-fed infants
10
.  
 
In addition to food carbohydrates, several intestinal bacteria can process host-derived 
carbohydrates, which are prominent constituents of mucosal layers. Besides providing 
carbon sources for bacterial growth, released host-derived carbohydrates influence gene 
expression in the microbiota, thereby affecting the virulence of pathogenic bacteria as 
demonstrated by the regulation of virulence factors in enterohaemorrhagic E. coli by fucose
11
. 
Other host-derived carbohydrates, such as sialic acids, are taken up by bacteria lacking de 
novo biosynthetic pathways for these sugars, and incorporated into bacterial capsule and 
lipooligosaccharides
12
. The decoration of bacterial glycoconjugates with sialic acid protects 
microbes from recognition by the host immune system
13
 and regulates the host immune 
response through interactions with sialic acid-binding lectins
14
. Finally, the interplay between 
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intestinal microbiota and host glycosylation is not limited to the utilization of host glycans by 
bacteria. Sialic acids as terminal residues on intestinal glycoconjugates are a prime target for 
bacterial adhesins and toxins from Vibiro cholerae, Helicobacter pylori and E. coli 
15-16
.   
 
The structural complexity of carbohydrates, either ingested in the form of milk 
oligosaccharides, or expressed as host-derived glycans, hampers the elucidation of their 
impact on the gut microbiota. Accordingly, little is known about the relevance of specific 
carbohydrates on microbiota composition and on intestinal physiology. The application of 
mice deficient for glycosyltransferases enables the investigation of interactions between 
defined carbohydrates, intestinal microbes, and the host immunity. For example, a study of 
α1,2 fucosyltransferase Fut2 knockout mice has recently demonstrated the interplay 
between fucosylated glycans and diet polysaccharides on shaping the gut microbiota
17
. The 
study of α2,3 sialyltransferase St3gal4  knockout mice (ST), which mediates 
α2,3-sialyllactose (3SL) synthesis in mammary gland, has established the role of the milk 
oligosaccharide on the gut microbiota and thereby on the susceptibility of mice in dextran 
sulfate sodium (DSS)-induced acute
18
 and chronic colitis
19
. Through the investigation of 
DSS-mediated colitis in ST mice and the modulation of the intestinal microbiota by selective 
antibiotic treatment, the present study reveals the critical role of α2,3-linked sialic acid in 
establishing a niche for intestinal E. coli after lactation and during intestinal inflammation.  
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Results 
Gut microbiota change during DSS induced colitis 
To unravel the relationship between α2,3-linked sialic acid and the intestinal microbiota, and 
to identify the mechanisms of α2,3-linked sialic acid effects on colitis development, we have 
first addressed the impact of intestinal bacterial groups on colitis by treating mice with a 
panel of antibiotics. Correlations between the resulting changes in microbial composition 
and susceptibility to DSS-mediated colitis pointed to specific bacterial families possibly 
regulating the severity of colitis in wild type (WT) and ST mice. In fact, the composition of 
colonic bacteria in WT and ST mice differed at the adult stage. The most abundant bacterial 
family in WT mice was Ruminococcaceae, reaching 44% of total bacteria. By contrast, 
Ruminococcaceae only represented 10% of colonic bacteria in ST mice, whereas 
Porphyromonadaceae dominated by reaching 37% (Fig. 1a). The bacterial composition of 
mice undergoing intestinal inflammation induced by DSS changed dramatically, as seen by a 
strong expansion of Bacteroidaceae and Enterobacteriaceae in WT mice. ST mice, which 
were less susceptible to DSS than WT mice , also showed increased Bacteroidaceae levels 
during DSS challenge, whereas Enterobacteriaceae remained at low level. Sequence analysis 
at the genus level indicated that the Escherichia and Shigella accounted for the observed 
increase of Enterobacteriaceae in WT mice, and Bacteroides accounted for the increase of 
Bacteroidaceae in both WT and ST mice under DSS challenge (Fig. 1b). 
 
Antibiotics effect on DSS induced colitis 
To determine whether a specific group of bacteria accounted for the different response to 
DSS, we treated WT mice with a panel of antibiotics before DSS challenge. Vancomycin, 
neomycin and penicillin exacerbated the severity of DSS-induced colitis as monitored by loss 
of body weight (Fig. 2a). Streptomycin was the only antibiotic that attenuated the loss of 
body weight during colitis, whereas chloramphenicol and metronidazole did not have much 
impact on the course of the inflammatory response (Fig. 2a). To exclude any damaging effect 
caused by the use of antibiotics on intestinal barrier function, we assessed epithelial 
permeability by measuring the leakage of orally administered FITC-dextran into the 
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bloodstream. Permeability was only significantly increased after DSS ingestion, but not after 
antibiotic treatment (Fig. 2b). We also tested the effect of a short-term treatment with 
antibiotics to exclude possible adaptations of the host mucosa to three weeks of altered 
microbiota composition. Focusing on vancomycin (Fig. 2c) and streptomycin (Fig. 2d), we 
could reproduce the worsening and improving effects of these two antibiotics by only 
administering vancomycin and streptomycin during DSS challenge. The protective effect of 
streptomycin towards DSS challenge was even more pronounced in a short term treatment 
compared with a three week pre-treatment in both WT and ST mice. The extent of intestinal 
inflammation was confirmed by measuring the length of the colon in treated mice. The 
shortening of colon length induced by DSS ingestion was aggravated by vancomycin and 
reduced by streptomycin (Fig. 2e). The impact of vancomycin and streptomycin treatment on 
the intestinal microbiota of WT mice was analyzed by 16S rRNA pyrosequencing and 
compared to the changes observed during DSS challenge. Vancomycin induced a strong 
increase of Enterobacteriaceae, which raised to 27% of total bacteria, whereas 
Enterobacteriaceae remained below 0.1% of total bacteria in streptomycin-treated mice (Fig. 
2f). Under both antibiotics, Bacteroidaceae expanded to represent the major bacterial family, 
but the increase in Bacteroidaceae did not directly correlate with the severity of DSS-induced 
colitis. In contrast, the abundance of Enterobacteriaceae correlated with the magnitude of 
colitis. Overgrowth of Enterobacteriaceae and several Bacteroidaceae spp. during intestinal 
inflammation is well documented, although the mechanisms underlying such expansions 
have not been identified in previous studies
20-21
. 
 
Expansion of E. coli during DSS induced colitis 
To verify which species of Enterobacteriaceae expanded during intestinal inflammation, we 
applied specific primers targeting the β-glucuronidase uidA gene22 and confirmed a 
significant increase of E. coli in DSS-challenged mice and in vancomycin-treated mice (Fig. 3a). 
In contrast, a significant reduction of E. coli was observed in both WT and ST mice treated 
with streptomycin. Overall, E. coli levels correlated with the severity of colitis in all genotypes 
and antibiotic treatments tested. Of note, the level of E. coli in adult ST mice was 2 orders of 
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magnitude lower than in WT mice, indicating that decreased exposure to α2,3-linked sialic 
acid, because of reduced sialylation of host glycans and the absence of 3SL in milk ingested 
during lactation, was accompanied by low level of intestinal E. coli. The importance of milk 
3SL during lactation at promoting the low-level colonization of E. coli was also visible in WT 
mice that were fostered by ST mother during lactation. WT mice fed on 3SL-deficient milk 
(WTXF) showed lower E. coli levels than littermates fed on normal milk. Similarly, ST mice fed 
on normal milk showed elevated E. coli levels compared with littermates fed on 3SL-deficient 
milk (Fig. 3b). The relative abundance of intestinal E. coli in cross-fostered mice also reflected 
the severity of DSS-induced colitis
18
. Overall, these data confirmed that neonatal exposure to 
milk 3SL contributed to the bacterial colonization of the intestine, especially by E. coli, and 
pointed to a role of E. coli in affecting the severity of colitis induced by DSS.  
 
Exposure to sialic acid promotes E. coli expansion 
To address the impact of 3SL on E. coli proliferation, we isolated various strains of commensal 
E. coli from the colon of WT mice during DSS-induced colitis. The identity of the isolated 
bacteria with E. coli was confirmed by sequencing universal stress protein uspA gene
23
, 
gyrase gyrB gene
24
 and by biochemical testing using the API20E Enterobacteriaceae 
detection system. The culture of the isolated E. coli strain EHV2 in minimal medium 
containing unique monosaccharides as carbon source confirmed that N-acetylneuraminic 
acid was a preferential sources of energy for E. coli (Fig. 4a). In contrast to free 
N-acetylneuraminic acid, the milk oligosaccharides 3SL and α2,6-sialyllactose (6SL) did not 
support E. coli growth in vitro (Fig. 4b). Proliferation could however be restored by adding 
sterile-filtered caecal fluid from WT mice to the culture medium, whereas E. coli growth was 
more robust in 3SL than in 6SL containing minimal medium. Because E. coli do not produce 
sialidases, the restoration of bacterial growth pointed to the presence of an α2,3-preferential 
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sialidase activity in caecal fluid. Such a sialidase activity was confirmed in caecal fluid and 
shown to increase significantly during DSS-induced colitis in both WT and ST mice (Fig. 4c). 
The substrate specificity of this caecal fluid sialidase was demonstrated by HPLC analysis 
after incubation of 3SL with caecal fluid (Supplementary Fig. 1). The sialidase activity was 
also increased in the caecal fluid of WT mice treated with streptomycin or vancomycin. By 
contrast, the sialidase activity was strongly decreased in WT mice treated with a broad 
spectrum antibiotic cocktail consisting of ampicillin, vancomycin, metronidazole, and 
neomycin, which supported the bacterial origin of the sialidase activity in caecal fluid (Fig. 
4d). To identify the source of this sialidase activity, we focused on bacterial groups, such as 
commensal Bacteroides and Bifidobacteria species that are known to secrete sialidases
25
. 
Host derived sialidases were unlikely candidates since vertebrate sialidases are unstable as 
soluble proteins in the extracellular space
26
. 
 
Bacteroides vulgatus sialidase releases sialic acid 
As Bacteroides species were strongly increased in the gut of mice challenged with DSS (Fig. 
1b) as well as in mice treated with streptomycin or vancomycin (Fig. 2f), we searched for 
sialidase genes in the caecum of DSS-challenged mice using a series of PCR primers 
encompassing known Bacteroides sialidase sequences in the glycoside hydrolase family 33 of 
the Cazy database. This analysis revealed a 100-fold increase in copy number of the 
Bacteroides vulgatus BVU_4143 sialidase gene (Gene ID: 5305102) in WT mice treated with 
DSS, whereas no change was detected in ST mice (Fig. 4e). The abundance of B. vulgatus also 
increased accordingly in the colon of WT mice during DSS-induced colitis (Supplementary Fig. 
2). Moreover, the abundance of the BVU_4143 sialidase gene increased in WT mice treated 
with streptomycin and vancomycin, but decreased in mice treated with antibiotic cocktail 
(Fig. 4f). The sialidase activity of BVU_4143 was confirmed after expression as a recombinant 
protein by demonstrating its ability to hydrolyze the aryl substrate 4-MU-NeuNAc 
(Supplementary Fig. 3a) and pNP-NeuNAc (Supplementary Fig. 3b). The sialidase activity of 
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recombinant BVU_4143 was inhibited by the sialidase inhibitor 
N-acetyl-2,3-didehydro-2-deoxyneuraminic acid (Neu5Ac2en) and lost by heat treatment. 
The addition of recombinant BVU_4143 to minimal media containing 3SL or 6SL enabled the 
growth of E. coli EHV2 on these oligosaccharides (Supplementary Fig. 3c), as observed for 
the restoration of E. coli EHV2 proliferation by addition of sterile-filtered caecal fluid to 
culture medium containing 3SL and 6SL (Fig. 4b). Overall, these results indicate that the 
expansion of B. vulgatus and the concomitant increased sialidase activity during DSS-induced 
colitis enables the sialic acid-dependent outgrowth of E. coli during inflammation. 
 
Sialic acid is required for sustaining E. coli colonization 
The dependence of E. coli on sialic acid in vivo was investigated by deleting the sialic acid 
transporter nanT gene
27
. Disruption of nanT, the first committed step in the sialic acid 
utilization pathway, abolished growth of the mutant E. coli strain in a sialic acid-containing 
minimal medium, but not growth in glucose containing medium (Fig. 5a). By contrast, the 
disruption of mannose transporter ManX did not affect the growth of E. coli in both glucose 
and sialic acid-containing medium. To investigate the in vivo colonization efficiency, nanT 
mutant and parental E. coli were gavaged at equal amounts of each 10
6
 cells to 
ampicillin-pretreated mice. Colonization efficiency was determined over a period of 10 days 
after inoculation by counting E. coli isolated from freshly isolated feces samples. Both strains 
were colonized at 10
8
-10
9
 colony-forming units per gram feces in WT mice by two days after 
inoculation. Parental E. coli remained stable over 10 days, but nanT mutants decreased 
dramatically over the same period (Fig. 5b). The same experiment performed in ST mice 
showed that even parental E. coli did not maintain their original levels in an environment 
deficient of α2,3-linked sialic acid (Fig. 5c). The comparison of competitive index between 
parental and nanT E. coli in the intestines of WT and ST mice suggested that the growth 
advantage of parental E. coli was associated with the local availability of sialic acid (Fig. 5d). 
The levels of free Neu5Ac in the caecal fluid were indeed higher in WT mice than in ST mice 
(Fig. 5e), thereby correlating with the occurrence of intestinal E. coli in WT and ST mice (Fig. 
3a). The concentrations of Neu5Ac measured in the caecum of WT mice treated with 
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streptomycin and vancomycin (Fig. 5f) also matched the abundance of E. coli in these mice 
(Fig. 3a). In the late-stage of DSS-induced colitis, the levels of free Neu5Ac decreased in WT 
mice and relatively increased in ST mice, which reflected increased sialic acid usage by E. coli 
and increased sialidase activity (Fig. 4c) during intestinal inflammation. Accordingly, these 
results were consistent with the hypothesis that E. coli outgrowth in the intestine depends 
on the release of sialic acid from host glycans. 
 
Sialidase inhibition lowers E. coli expansion and colitis 
Based on the requirement for sialidase activity to cleave α2,3-linked sialic acid and to 
promote E. coli proliferation during intestinal inflammation, we hypothesized that sialidase 
inhibition would decrease both the expansion of E. coli during DSS-induced colitis and the 
severity of the inflammatory response. We first confirmed the effectiveness of the sialidase 
inhibitor Neu5Ac2en at preventing E. coli growth in presence of 3SL and caecal fluid in vitro 
(Fig. 6a).  Next, we confirmed the effectiveness of Neu5Ac2en at reducing the release of 
sialic acid in vivo by showing decreased levels of free Neu5Ac in the caecum of WT mice 
treated with the sialidase inhibitor (Fig. 6b). Oral administration of Neu5Ac2en to WT mice 
during DSS challenge also prevented the outgrowth of E. coli during inflammation, as seen by 
a decrease of E. coli levels by 2-3 orders of magnitude (Fig. 6c), and decreased the severity of 
DSS-induced colitis as assessed by change in body weight (Fig. 6d) and colon length (Fig. 6e). 
Neu5Ac2en treatment also reduced the loss of colonic architecture and leukocyte infiltration 
(Fig. 6f), although without reaching statistical significance (Fig. 6g). Neu5Ac2en treatment 
was by contrast ineffective in ST mice challenged with DSS (Supplementary Fig. 4), which was 
expected considering the low levels of sialidase-producing Bacteroides spp. and low sialidase 
activity in the caecum of ST mice. Overall, these data demonstrated that inhibition of caecal 
sialidase activity significantly reduced the outburst of E. coli and hence the severity of colitis 
in mice. 
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E. coli intensifies dendritic cell activation 
The question as to how E. coli proliferation affected intestinal inflammation remained open. 
We therefore assessed the pro-inflammatory potential of E. coli on intestinal CD11c
+
 
dendritic cells (DCs). Previous work has shown increased CD11c
+
 DC infiltration to the colonic 
mucosa of WT mice compared to ST mice, suggesting a critical role of DCs during intestinal 
inflammation
19
. We examined the stimulatory effect of E. coli EHV2 and of the Bacteroides 
thetaiotaomicron on mesenteric lymph node-derived CD11c
+
 DCs. B. thetaiotaomicron was 
chosen as reference because Bacteroides represents a major group of intestinal bacteria, 
which expanded in both WT and ST mice during DSS-mediated colitis (Fig. 1b). Stimulation of 
CD11c
+
 DCs with fixed E. coli increased the expression of the activation markers MHC-II, 
CD86, and CD40, whereas stimulation with fixed B. thetaiotaomicron failed to activate 
CD11c
+
 DCs (Fig. 7a). The pro-inflammatory effect of E. coli was not limited to mouse DCs as 
stimulation of the human monocytic cell line THP-1 also increased the expression of the 
activation marker CD54 (Fig. 7b). The effect of E. coli was even more pronounced when 
measuring the secretion of pro-inflammatory cytokines from stimulated mouse CD11c
+
 DCs. 
The levels of IL-6, TNF-α, and IL-12p40 produced after E. coli stimulation exceeded those 
reached after stimulation with LPS at 500 ng ml
-1
. Under identical conditions, B. 
thetaiotaomicron did not increase cytokines production (Fig. 7c). 
 
Overall, this study demonstrated that the expansion of commensal E. coli following the 
alteration of epithelial integrity caused by DSS uptake was mediated by increased exposure 
to sialic acid, and that overgrowth of E. coli exacerbated intestinal inflammation by 
stimulating the release of pro-inflammatory cytokines from intestinal DCs. 
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Discussion 
Multiple studies have documented that intestinal inflammation is frequently accompanied by 
imbalanced microbiota. Such a dysbiosis is often characterized by a relative increase of 
facultative anaerobic Enterobacteriaceae
28
. Different factors such as nitrate
29
 and 
enterobactin
30
 promote Enterobacteriaceae expansion. The present study underlines the 
contribution of host glycosylation, specifically of α2,3-linked sialic acids, in enabling the 
proliferation of Enterobacteriaceae during intestinal inflammation in mice. Exposure to 
α2,3-linked sialic acids begins during lactation with the uptake of the milk oligosaccharide 
3SL. After weaning, sialylated host glycans constitute the main source for the carbohydrate. 
Whereas Enterobacteriaceae genomes encode various glycosidases, bacteria such as E. coli 
cannot digest sialylated oligosaccharides. Therefore, their growth relies on scavenging free 
monosaccharides released by glycosidases of other bacteria. Our comparative study of 
monosaccharides showed that the sialic acid yielded the fastest growth of E. coli among the 
main monosaccharides encountered in mammalian glycans. This finding is consistent with 
previous work showing that sialic acid catabolism conferred a growth advantage to intestinal 
E. coli 
31-32
. 
The growth advantage provided by sialic acid was dependent on a sialidase displaying a 
preference for α2,3-linked over α2,6-linked sialic acids, and which increased during intestinal 
inflammation. Commensal E. coli do not express sialidases to liberate host sialylated glycans, 
therefore the access to bound sialic acids depends on secreted sialidases, such as the 
BVU_4143 sialidase identified in our study. We also detected other sialidase genes in 
colitogenic mice, such as sequences sharing similarity with sialidase genes encoded by 
Bacteroides fragilis and Parabacteroides distasonis, although the abundance of these 
sialidase sequences did not vary between mouse genotypes and during DSS-mediated colitis. 
The dependence of E. coli on sialidases secreted by Bacteroides spp. may explain the parallel 
increased abundance of Bacteroides spp. and E. coli observed in patients with colitis
33
. A 
recent study also demonstrated that the commensal sialidase-producing B. thetaiotaomicron 
was associated with proliferation of Salmonella enterica typhimurium and Clostridium 
difficile
34
. By contrast, colonization of mice with a sialidase-deficient mutant reduced free 
sialic acid levels and thereby impaired the expansion of C. difficile. 
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The decreased severity of DSS-induced colitis in mice treated with sialidase inhibitor 
demonstrated the contribution of sialic acid in E. coli expansion and in the ensuing 
inflammatory response. Administration of free sialic acid to mice prior or during DSS 
challenge however failed to affect the levels of intestinal E. coli and the severity of colitis 
(Supplementary Fig. 5). Considering that monosaccharides are absorbed in the small 
intestine and only minute amounts reach the colon, oral supplementation with sialic acid is 
thus unlikely to influence the outgrowth of E. coli in the colon. Therefore, the release of sialic 
acid from host glycans is critical in promoting the growth advantage of E. coli. The increase in 
sialylation of intestinal mucins during colitis
35-36
 likely facilitates the local release of free sialic 
acid during inflammation. 
 
Our findings showed that commensal E. coli was a potent activator of a pro-inflammatory 
response in intestinal DCs. The activation of DCs was likely induced by surface 
lipopolysaccharides (LPS) triggering Toll-like receptor-4 signaling. The strong pyrogenic effect 
of commensal E. coli over the one induced by B. thetaiotaomicron matches previous findings 
showing that E. coli LPS was more active than Bacteroides spp-derived LPS at inducing TNFα 
production
37
. Similar differences in pyrogenicity were also noted in mouse models
38-39
. These 
results demonstrate that increased E. coli levels likely exacerbate inflammation through 
activation of mucosal immune cells such as DCs. Several intestinal bacteria regulate mucosal 
immunity, thereby affecting the occurrence of Th17 cells in the lamina propria in the case of 
segmented filamentous bacteria
40-41
, or the induction of Foxp3
+
 Treg cells in the case of a 
group of Clostridium spp
42
 and Bacteroides fragilis
43
. We cannot exclude that the 
disappearance of inflammation-lessening bacteria also affects the severity of colitis alongside 
the expansion of pro-inflammatory E. coli, but such contributions are unlikely since we failed 
to detect any differences in the distribution and amounts of mucosal immune cells between 
WT and ST mice prior to DSS-induced colitis
18
. Therefore, we conclude that the proliferation 
of E. coli supported by α2,3-linked sialic acids was the main factor regulating the magnitude 
of intestinal inflammation triggered by DSS ingestion. 
 
This study demonstrated the critical role of α2,3-linked sialic acids provided by milk-derived 
3SL during lactation and by host mucosal glycans in establishing an intestinal niche for E. coli 
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in mice. Expansion of E. coli during colitis directly depended on sialic acid release from host 
glycans after sialidase activity. This resulting overgrowth of E. coli leads to exacerbation of 
the proinflammatory response by intestinal DCs. The beneficial outcome of sialidase 
inhibition on the severity of DSS-induced colitis suggests that sialidase inhibitors should be 
investigated as agents able to reduce intestinal inflammation by preventing dysbiosis 
manifested by Enterobacteriaceae expansion. 
 
Materials and Methods 
Bacterial DNA extraction and quantitative PCR 
DNA was isolated from fecal samples using the QIAamp DNA Stool Mini Kit (Qiagen) 
according to manufacturer’s instructions. Lysis temperature was increased to 95°C for 5 min 
to ensure complete cell lysis of Gram-positive cells. The proportion of bacterial family and 
genera in fecal samples were determined by real-time PCR using the EvaGreen qPCR Master 
Mix (Biotium). Cycling conditions were 40 cycles at 95°C for 10 s, 60°C for 10 s and 72°C for 
25 s after an initial denaturation at 95°C for 3 min. Primer pairs specific for 16S rRNA of 
Bacteroidetes (Bac32F, Bac303R), Enterobacteriaceae (Eco1457F, Eco1652R), and total 
bacteria (Eub338F, Eub518R) were described previously
44-45
. Primers (UAL1939b, UAL2105b) 
targeting β-glucuronidase uidA gene was used to evaluate the relative abundance of E. coli22. 
Quantification values were calculated by the 2
-△Ct
 method relative to total bacterial 16S 
rRNA amplicons
46
.  
 
16S rRNA pyrosequencing 
Fecal DNA was isolated from fresh stool samples of 7-week old WT and ST male mice before 
and at day 8 after initiation of DSS treatment. The 16S rRNA V5-V6 region was amplified from 
fecal DNA samples using primer 784F and 1061R
47
. Amplicons were sequenced using a Roche 
454 GS-FLX system (DNA Vision, Belgium). The QIIME software was used for taxonomic 
classification. Taxonomy was assigned using Ribosomal database Project (RDP) classifier and 
the Greengenes database
48
. Bacterial diversity was determined at the phylum, family and 
genus levels. 
RESULTS 
 
84 
 
Mouse models 
Wildtype and sialyltransferase St3gal4
-/-
 mice
49
 were of C57BL/6 background and derived 
from the same breed and maintained in light-cycled and climate-controlled facility. Animals 
were received regular laboratory chow diet (KLIBA extrudat No. 3436, Provimi Kliba, SA 
Switzerland) and sterile water ad libitum. Synchronized matings were set up for WT and ST 
mice to allow the exchange of newborn mice for cross-fostering experiments. All 
experiments were performed in compliance with the Swiss Animal Protection Ordinance and 
approved by the Veterinary Office "of the Canton of Zurich, Switzerland.  
 
Antibiotic treatment and DSS induced colitis 
Six to seven week-old, male mice were treated with 3-3.5% (w/v) DSS (MW = 36-50 kDa; MP 
Biomedicals) in drinking water for 5 days, followed by a supply of normal water until sacrifice 
of the animals. Body weight and physical activity were monitored daily. For long term 
antibiotic treatment, 3-week-old mice were provided with sterile drinking water 
supplemented with vancomycin (0.5 g L
-1
), streptomycin (1 g L
-1
), neomycin (1 g L
-1
), 
chloramphenicol (0.5 g L
-1
) or metronidazole (1 g L
-1
) plus aspartame (0.25%, w/v) for 3 
weeks prior to the beginning of DSS treatment.  
 
Transepithelial permeability assay 
Mice were gavaged with 600 mg kg
-1
 body weight of FITC-dextran (MW 3000-5000, Sigma) 
and whole blood was collected by cardiac puncture 4 h after gavage. Blood serum was 
collected after centrifugation at 1500 x g for 10 min. Serum fluorescence intensity was 
measured using a multi-detection microplate reader (Tecan Infinite M200 Pro, Switzerland) 
with an excitation wavelength of 485 nm and an emission wavelength of 535 nm. FITC 
concentration (μg ml
-1
) was calculated from a standard curve using serial dilutions of 
FITC-dextran
50
. 
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Bacterial strains and mutant construct 
E. coli strain EHV2 was isolated from inflamed colon surface of DSS-treated C57/BL6 mice. 
The isolate strain was confirmed by 16S rRNA sequencing, universal stress protein uspA
23
, 
gyrase gyrB
24
 sequencing, and phenotypic analysis (API-20E Enterobacteriaceae 
identification kit; bioMerieux). E. coli strain HS996 was obtained from Genebridge and 
transformed with pET16b vector containing an ampicillin resistance gene. HS996-nanT 
knockout mutant was constructed by introducing a kanamycin-resistance cassette by 
homologous recombination into the nanT locus with followed by manufacture’s instruction 
(Genebridge, Germany). The genomic primers used for the targeting construct were designed 
according to the flanking regions of the E. coli nanT gene: forward primer f182 was 5’-ATA 
CCA AAG CGT GTG GGC ATC GCC CAC CGC GGG AGA CTC ACA ATG AGT ACA ATT AAC CCT CAC 
TAA AGG GCG-3’, and reverse primer r1723 was 5’-GCA ACA GGA TTA ACT TTT GGT TTT GAC 
TAA ATC GTT TTT GGC GCT GCC AAT AAT ACG ACT CAC TAT AGG GCT C-3’. Null mutation at 
the nanT locus was confirmed by genome sequencing and growth phenotype. B. 
thetaiotaomicron (DSM 2079
T
) was obtained from the German collection of microorganisms 
and cell cultures (Braunschweig, Germany). Cells were grown in YCFA medium containing 
volatile fatty acids
51
 at 37°C anaerobically in rubber-sealed Hungate tubes. Cell density was 
measured by a spectrophotometer at 600nm (S2100 Diode array, Biochrom WPA). 
 
Carbohydrate metabolism assay 
E. coli EHV2 (10
7
 cells) were cultured in 3 ml of M9 minimal medium
52
 containing 10 mM of 
either glucose (Glc), galactose (Gal), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine 
(GalNAc), fucose (Fuc) and N-acetylneuraminic acid (Sia) as single carbohydrate source at 
37°C for 24 h. The milk oligosaccharides 3SL and 6SL were tested as 5 mM in 3 ml of M9 
minimal medium supplemented with phosphate buffered saline (PBS) or sterile filtered 
mouse caecal fluid (1.5%, v/v).  All neutral monosaccharides were purchased from 
Sigma-Aldrich except N-acetylneuraminic acid from Carbosynth (Berkshire, UK).The 
oligosaccharides 3SL and 6SL were obtained from Glycom A/S (Lyngby, Denmark). Cell 
density was determined by OD 600 values at 3, 6, 12 and 24 h. For determination the growth 
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phenotype in nanT mutant and ManX mutant, parental and mutant strains were cultured in 
modified M9 minimal medium (additional 0.003% L-Histidine, 0.004% Leucine, and 0.01% 
Yeast extract) containing 10 mM of glucose or N-acetylneuraminic acid. 
 
Sialidase activity assay  
Mouse caecal content was collected and centrifuged at 15’000 x g for 10 min at 4°C. The 
supernatant was filtered through a 0.45 μm membrane to yield caecal fluid. The fluorogenic 
substrate 2’-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid sodium salt (4-MU-NeuNAc; 
Carbosynth) was used to determine sialidase activity. In brief, caecal fluid (10%, v/v) was 
incubated with 0.1 mM 4-MU-NeuNAc in 0.2 ml of 100 mM sodium acetate buffer (pH 7.4) at 
37 °C for 15 min. Assays were stopped by adding 0.8 ml of 0.5 M sodium carbonate buffer 
(pH 10.5) and further diluted 20-fold prior to fluorescence measurement. Cleaved 
4-methylumbelliferone (4-MU) was measured by fluorescence detection in a multi-detection 
microplate reader at an excitation wavelength of 360 nm and an emission wavelength of 440 
nm
53
.  
 
Quantitative PCR of bacterial sialidase genes  
Sequences of sialidase (EC 3.2.1.18) genes from Bacteroidaceae were retrieved from the 
GH33 sialidase family of the Cazy database. Primers encompassing conserved DNA stretches 
of sialidase genes from P. distasonis, B. vulgatus, B. thetaiotaomicron, B. fragilis were 
designed based on multiple alignment analysis. The lack of significant sequence similarity of 
the selected primers with unrelated bacterial sequences was confirmed by BLAST analysis. 
The B. vulgatus sialidase primers used for quantitative PCR analysis were Bv-f266: 
GGAGGGGAAAGACTTATTTTGC, Bv-r501: TTCCACCACTTCTGCCGAC; Cycling conditions were 
40 cycles at 95°C for 10 s, 60°C for 10 s and 72°C for 25 s after an initial denaturation at 95°C 
for 3 min. Quantification values are represented as gene copy numbers per μg of total fecal 
DNA. 
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Molecular cloning and purification of sialidase 
The gene encoding B. vulgatus_4143 sialidase (GeneID: 5305102) was amplified by PCR using 
the genomic DNA from caecum sample in WT-DSS mouse as template. NdeI and BamHI sites 
were introduced in the forward Bvu_4143F 5’- GGCCATATGAGAAACCCTAGCTTATTA -3’ and 
reverse primer Bvu_4143R: 5’- GCGGGATCCTTATTTGGTCTTAATAAT -3’, respectively. PCR 
conditions were thirty cycles of 30 s at 95°C, 30 s at 53°C, 3.5 min at 72°C. The PCR product 
was digested with NdeI and BamHI and subcloned into the pET16b expression vector 
(Novagen). The pET16b- BVU_4143 vector was transformed into E. coli BL21-star (DE3) cells 
(Invitrogen) cultured in LB broth and supplemented with ampicillin (100 μg ml
-1
) at 37°C. On 
reaching an OD600 value of 0.5, BVU_4143 expression was induced by adding 0.5 mM IPTG 
and incubating bacteria at 30°C for 5 h. Bacteria were then resuspended in 100 mM Tris-HCl 
plus 20 mM imidazole (pH 7.4) and disrupted by sonication. The resulting cell extract was 
incubated with Ni-sepharose (GE Healthcare Life Science) at 4°C overnight, washed with 100 
mM Tris-HCl containing 40 mM imidazole and the His6-tagged BVU_4143 sialidase was eluted 
with 500 mM imidazole. 
 
Bacterial colonization fitness assay 
The relative fitness of E. coli strains for colonization of the mouse intestine was monitored as 
described
34
. Briefly, 6 week-old WT mice were given drinking water containing ampicillin (2 
mg ml
-1
) for 2 days prior to gavage with 10
6
 colony-forming units of parental HS996-amp
r
 and 
HS996-nanT mutant::Kana
r
 E.coli. Fresh fecal samples were collected, serially diluted and 
plated on LB agar containing ampicillin (100 μg ml
-1
) or ampicillin plus kanamycin (30 μg ml
-1
) 
by day 1, 2, 5 and 10 after gavage. Competitive index was calculated as the ratio of parental 
to nanT mutant E. coli.  
 
Quantification of caecal sialic acids 
Mouse caecal content (approximately 500 mg) was weighed out and centrifuged for 10 min 
at 16,000 x g at 4°C. The supernant was collected and filtered through 0.45 μm cronus HPLC 
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membrane to get caecal fluid and stored at -20°C before use. Caecal fluid was derivatized 
with 1,2-diamino-4,5-methylene-dioxybezene (DMB; Sigma-Aldrich) as described previously
54
. 
In brief, 10 μl of caecal fluid was incubated with 200 μl of the DMB solution at 50°C for 2.5 h 
in the dark. DMB solution was prepared by dissolving DMB dihydrochloride (7 mM) in 1.4 M 
acetic acid containing 0.75M β-mercaptoethanol and 18 mM sodium hydrosulfite. The 
reaction was stopped by adding 800 μl of ice-cold distilled water. The derivatized product 
was analyzed by reverse-phase HPLC using a ODS Hypersil 150 x 3 mm column (Thermo 
scientific). The mobile phase was acetonitrile:methanol:water (9:7:84, v/v) at a flow rate of 
0.3 ml min
-1
. Florescence of the derivatized product was monitored at 373nm (excitation) 
and 448nm (emission). DMB-derivatized Neu5Ac was identified by comparison with 
authentic sialic acid standards. 
 
Sialidase inhibition 
The sialidase inhibitor N-acetyl-2,3-didehydro-2-deoxyneuraminic acid (Neu5Ac2en) was 
prepared in house based on published procedures
55
. For in vitro inhibition, E. coli EHV2 was 
cultured for 24 h at 37°C in M9 minimal media containing 5mM 3SL, caecal fluid (1.5%, v/v) 
and varying Neu5Ac2en concentrations. For in vivo inhibition, mice were anesthetized 
by isoflurane inhalation, gavaged with 300 μl of Neu5Ac2en (10 mg kg
 -1
 per day) in sterile 
saline at days 0, 1, 2, 5 of DSS challenge. Control groups received sterile saline. 
 
Histological staining of colonic tissue 
Distal colons were removed, cut longitudinally, and fixed in 10% neutral buffered formalin 
then embedded in paraffin. Tissue samples were cut in serial 5-μm sections, which were 
stained with hematoxylin-eosin (Sigma-Aldrich). Histological sections were examined by 
using microscope Zeiss Axio Imager.Z2, objectives (Zeiss EC Plan – Neofluar 10x /0,3). Image 
was acquired by Zeiss AxioCam HrC camera and analyzed with Zeiss AxioVision software 
(AxioVs40V4.8.2.0). Sections were scored individually by an independent investigator blinded 
to the type of treatment. Morphological changes and leukocyte infiltration in the colon were 
scored as previously described
56
. The total score is represented as the sum of the epithelium 
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and infiltration score.  
 
DC Isolation and stimulation  
Mesenteric lymph nodes were isolated and incubated in 2.5 mg ml
-1
of collagenase type D 
(Roche) in RPMI 1640 containing 10% FCS for 10 min at 37°C. Tissues were gently 
homogenized by passing through an 18-gauge needle, then incubated for 30 min at 37°C. The 
resulting cell suspensions were filtered through 40 μm cell strainers and incubated with 
Fc-blocker (anti-CD16/32) (eBioscience) for 10 min. CD11c
+
 cells were isolated with 
anti-CD11c MicroBeads (Miltenyi Biotec) according to the manufacturer’s instructions. 
CD11c
+
 DCs (2×10
5
 cells per ml) were culture in RPMI 1640 containing 10% FCS, and 
stimulated with fixed bacteria or PBS for 14 h at 37°C. E. coli (EHV2) and B. thetaiotaomicron 
(DSMZ 2079T) were fixed in 0.5% paraformaldehyde for 15 min at room temperature and 
washed with PBS prior to stimulation. Fixed bacteria were co-cultured with dendritic cells in 
a ratio 100:1. After stimulation, dendritic cells were stained with fluorochrome-labeled 
anti-mouse antibodies: MHCII-FITC (BD Bioscience), CD86-PE (eBioscience), CD40-PE-Cy7 
(Biolegend), and CD11C-APC (BD Bioscience) for 30 min at 4°C. Cells were analyzed by flow 
cytometry (FACScanto II). For monocytes stimulation, human THP-1 cells (1x10
6
 cells per ml) 
were stimulated with bacteria or PBS for 14 h as described above, but in bacteria to cells 
ratios of 5:1 and 1:1. After stimulation, THP-1 cells were stained with CD54-PE (BD Bioscience) 
for 30 min at 4°C and analyzed by flow cytometry. The supernatants of stimulated DCs were 
collected and analyzed for IL-6, IL-10, IL-12p40, and TNF-α cytokine production by multiplex 
bead array (Cytolab AG, Switzerland). 
 
Statistical analysis 
Results are presented as mean ± SEM unless specified. Difference between groups was 
analyzed by unpaired Student’s t-test (two-tailed) and one-way ANOVA with Bonferroni’s 
multiple comparison post-test using GraphPad Prism 5. P values below 0.05 were considered 
significant. 
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Figure legends 
Figure 1. Bacterial composition of mice in DSS-induced colitis. (a) 16S rRNA pyrosequencing 
analysis of fecal microbial taxa families in control and DSS-treated WT and ST mice (at day 8 
after DSS addition). (b) Pyrosequencing analysis of fecal microbial taxa in the genus level. 
Data show the average percentage of total identified sequences obtained from a pool of 8 
mice per group. Only the bacterial taxa representing at least 1% of total identified sequences 
are presented. 
 
Figure 2. Antibiotics effect on DSS-induced colitis. (a) Mice were treated with vancomycin 
(Van), neomycin (Neo), penicillin (Pen), streptomycin (Stp), chloramphenicol (CAM), and 
metronidazole (Met) for 3 weeks before DSS challenge for 5 days. Body weight was measured 
by day 8 after initiation of DSS challenge and given as percentage to the body weight of mice 
challenged with DSS without antibiotics. The data is represented as mean ± SEM. N=6-8, *p < 
0.05 (two-tailed Student’s t-test) (b) Intestinal permeability was measured by FITC-dextran 
levels in serum from control, colitogenic mice on day 5 of DSS challenge, and 3 weeks of 
antibiotic pre-treated mice. N=5, *p < 0.05 (ANOVA, Bonferroni’s multiple comparison test) (c) 
Relative change in body weight of WT and ST mice treated with 0.5 g L
-1
 vancomycin (Van) for 
7 days and 3% DSS for 5 days; control mice received DSS without vancomycin. (d) Relative 
change in body weight of WT and ST mice treated with 1 g L
-1
 streptomycin for 8 days and 3% 
DSS for 5 days. (e) Colon length was determined at the endpoint of DSS treatment. In (c-e) 
the data is represented as mean ± SEM from two independent experiments, N=6-8, *p < 0.05 
(ANOVA, Bonferroni’s multiple comparison test).  (f) 16S rRNA pyrosequencing analysis of 
fecal microbial taxa families in untreated WT mice, in vancomycin (Van), streptomycin 
(Stp)-treated WT mice, and DSS challenged WT mice (WT-DSS). The data is represented as 
the percentage of total identified sequences obtained from a pool of 8 mice per group.  
 
Figure 3. Intestinal E. coli in mice. Relative abundance of E. coli was determined by real-time 
PCR using specific uidA primers and quantified using the 2
-△Ct
 method. (a) Relative 
abundance of E. coli in groups of 6 week-old WT and ST mice treated with the antibiotics 
vancomycin (Van) and streptomycin (Stp) and challenged with 3% DSS. Mice were received 
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with or without 8 days of antibiotic treatment and DSS for the first 5 days in drinking water. 
Control mice received sterile drinking water. (b) Relative abundance of E. coli in 6 week-old 
WT, ST and respectively cross-fostered (XF) mice, which were fed by foster mothers of the 
other genotype during lactation. The data is represented as median value. Each point 
indicates a single mouse from two independent experiments. N=6-8, *p < 0.05 (ANOVA, 
Bonferroni’s multiple comparison test).  
 
Figure 4. Sialic acid processing and uptake by E. coli in vitro. (a) Growth of E. coli EHV2 in 
M9 minimal medium containing single monosaccharide at 10 mM. Sia, N-acetylneuraminic 
acid, Glc, glucose, GlcNAc, N-acetylglucosamine, GalNAc, N-acetylgalactosamine, Gal, 
galactose, Fuc, fucose. (b) Growth of E. coli in minimal medium containing 5mM of 3SL and 
6SL with and without supplementation of caecal fluid (CF, 1.5%, v/v) derived from WT mice. 
(c) Caecal fluid of conventional and DSS-challenged WT and ST mice were collected. Sialidase 
activity was determined by measuring fluorescent 4-MU-NeuNAc at 440 nm. (d) Sialidase 
activity was also measured in the caecal fluid of WT and WT mice treated with either 
streptomycin (Stp 1 g L
-1
), vancomycin (Van 0.5 g L
-1
), or antibiotic cocktail (AVMN: ampicillin, 
vancomycin, metronidazole, and neomycin). In (c-d) the data is represented as mean ± SEM 
from two independent experiments, N=5-8, *p < 0.05 (two-tailed Student’s t-test). (e) The 
abundance of the B. vulgatus BVU_4143 sialidase gene was determined by real-time PCR 
from caecum samples of WT and ST mice, and (f) caecum samples of antibiotic treated WT 
mice. The data is represented as gene copy number per μg of fecal DNA. In (e-f) each data 
point indicates a single mouse, N=5-7, * p < 0.05 (two-tailed Student’s t-test). 
 
Figure 5. Sialic acid catabolism is required for maintaining E. coli colonization.  (a) Growth 
of parental E. coli, nanT mutant, and ManX mutant in modified minimal media containing 10 
mM of glucose or sialic acid. (b) Relative fitness of parental E. coli and nanT mutant in 
colonization of WT mice and (c) ST mice. Bacterial colonization fitness were determined by 
counting colony forming unit (cfu) of serial diluted fecal feces collected at indicated time 
points. In (b-c) data are shown as median ± interquartile range. N =8, *p < 0.05 (two-tailed 
Student’s t-test). (d) Competitive index was calculated as ratio of parental E. coli to nanT 
mutant in WT and ST mice over 10 days after administration. The data is represented as 
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median value, and each dot indicates an individual animal. N =8, *p < 0.05 (two-tailed 
Student’s t-test). (e) Levels of free Neu5Ac in the caecal fluid of control and DSS-challenged 
WT mice were determined by HPLC analysis. (f) Levels of free Neu5Ac in the caecal fluid of 
control (C), streptomycin-, and vancomycin-treated mice measured 5 days post treatment. In 
(e-f) the data is represented as mean ± SEM from two independent experiments. N=6-8, *p < 
0.05 (ANOVA, Bonferroni’s multiple comparison test). 
 
Figure 6. Reduced intestinal E. coli expansion by sialidase inhibition. (a) In vitro growth of E. 
coli EHV2 in minimal media containing 10 mM Glc or 3SL and the presence of caecal fluid  
and inhibitor Neu5Ac2en (0, 20, 50, 100 μM). (b) Levels of sialic acid in the caecal fluid of 
control, and inhibitor-treated WT mice were measured by HPLC analysis. control mice were 
administered with sterile PBS. In (a-b) the data is represented as mean ± SEM from two 
independent experiments, N=5, *p < 0.05 (two-tailed Student’s t-test). (c) Relative 
abundance of intestinal E. coli in control (PBS-treated) and Neu5Ac2en-treated WT mice (10 
mg kg
-1
 per day) was determined at day 8 after initiation of DSS challenge. (d) Relative 
change in body weight of control and Neu5Ac2en-treated WT mice during DSS challenge for 
5 days. Arrowheads indicate the time points of Neu5Ac2en administration. (e) Colon length 
was measured at day 8 after initiation of DSS challenge. In (d-e) the data is represented as 
mean ± SEM from two independent experiments, N=6-8, *p < 0.05 (two-tailed Student’s 
t-test). (f) Representative histological sections of colon tissues from untreated WT mice 
(Mock), DSS-treated mice (DSS), and DSS-treated mice administered with sialidase inhibitor 
(DSS/Neu5Ac2en). Arrowheads indicate infiltrating leukocytes. Scale bar, 100 μm. (g) Scoring 
of colitis severity by quantitative examination of tissue alteration and leukocytes infiltration.  
 
Figure 7. Stimulation of dendritic cells and monocytes. (a) Bacteria were fixed with 0.5% 
paraformaldehyde in PBS, washed and co-cultured at a ratio of 100:1 with mouse mesenteric 
CD11c
+
 DCs. Ec, E. coli EHV2; Bt, B. thetaiotaomicron. Cell surface expression of CD86, CD40 
and MHC-II was analyzed by flow cytometry. (b) Human monocytic THP-1 cells were 
stimulated with fixed bacteria at ratios of 5:1 and 1:1 to cells for 14 h at 37°C. Cell surface 
expression of CD54 was analyzed by flow cytometry. In (a-b) the data is represented as mean 
fluorescence intensity MFI ± SEM from three independent experiments. N=6, *p <0.05. 
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(ANOVA, Bonferroni’s multiple comparison test). (c) Cytokine expression in the culture 
supernatant of stimulated mesenteric CD11c
+ 
DCs stimulated for 14 h at 37°C with fixed E. 
coli (Ec), B. thetaiotaomicron (Bt), and 500 ng ml
-1
 of LPS. PBS was used as negative 
stimulation control. Data is represented as mean ± SEM. N= 4-5, *p < 0.05 (ANOVA, 
Bonferroni’s multiple comparison test). 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
 
 
  
0 1 2 3 4 5 6 7 8 9 10
6
7
8
9
10
E. coli
E. coli ∆nanT
**
Days after colonization in WT mice
E.
 
co
li 
co
un
ts
 
(lo
g 
cf
u 
pe
r 
g 
fe
ce
s)
b a 
C Stp Van
0
100
200
300
400
500
*
*
*
Ca
ec
al 
Ne
u
5A
c
co
n
ce
n
tra
tio
n
 
( µM
)
WT WT-DSS ST ST-DSS
0
50
100
150
200
*
*
Ca
ec
al
 
Ne
u
5A
c
co
n
ce
n
tra
tio
n
 
( µM
)
10 - 1
100
101
102
103
Days after colonization
WT
ST
1d           2d            5d           10d
* *
Co
m
pe
tit
ive
 
In
de
x
(P
ar
en
ta
l /
n
an
T 
m
ut
an
t)
0 1 2 3 4 5 6 7 8 9 10
6
7
8
9
10
E. coli
E. coli ∆nanT
Days after colonization in ST mice
E.
 
co
li 
co
un
ts
 
(lo
g 
cf
u 
pe
r 
g 
fe
ce
s)
f e 
c d 
Glucose Sialic acid
0.0
0.4
0.8
1.2
1.6
2.0 E. coli
E. coli ∆nanT
E. coli ∆ManX
Ce
ll d
en
sit
y 
(O
D
 
60
0)
RESULTS 
 
104 
 
Figure 6 
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Supplementary Information 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Specificity of mouse caecum fluid sialidase. Cleavage of sialic acid 
from 3SL after incubation with caecum fluid for 16 h at 37
o
C. Reaction products were 
separated by HPLC using a CarboPac PA200 column (Dionex). Carbohydrates were identified by 
comparison with authentic standards. Lac, lactose; Sia, N-acetylneuraminic acid. 
Representative chromatograms from two independent experiments are shown.  
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Supplementary Figure 2. Relative abundance of B. vulgatus in the colon of mice. The relative 
abundance of B. vulgatus was determined by real-time PCR using TaqMan assay. Each data 
point represents a single mouse from two independent experiments, N=6-7, *p < 0.05 
(Two-tailed Student’s t-test). 
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Supplementary Figure 3. Characterization of B. vulgatus BVU_4143 sialidase. (a) Recombinant 
BVU_4143 was purified as His-tagged protein. Sialidase activity of recombinant protein was 
determined by the hydrolysis of 4-MU-NeuNAc and (b) pNP-NeuNAc. For sialidase inhibition, B. 
vul sialidase was pretreated with Neu5Ac2en for 20 min with final concentration 200 μM. Heat, 
heat inactivation at 95 
o
C for 10 min. (c) Growth of E. coli EHV2 in minimal medium containing 5 
mM of 3SL and 6SL with and without supplementation of recombinant sialidase. Data represent 
as mean ± SEM, N=4, ***p < 0.001 (Two-tailed Student’s t-test). 
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Supplementary Figure 4. Administration of sialidase inhibitor in ST mice. ST mice were 
administrated with PBS or Neu5Ac2en (10 mg/kg/day) at indicated time points (arrowhead) 
during DSS (3%) challenge for 5 days. Relative change in body weight in ST mice challenged with 
DSS was monitored daily, N=4. 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 5. Oral administration of sialic acid in WT mice. WT mice were orally 
gavaged with 300 μl of 100 mM sialic acid or sterile PBS at indicated time points (arrowhead) 
during DSS (3%, w/v) challenge for 5 days. Relative change in body weight was monitored daily, 
N=8, not significant (Two-tailed Student’s t-test). 
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Supplementary Methods 
 
Sialidase specificity assay  
The linkage specificity of caecum sialidase was determined by incubating 0.1 ml of 100 mM 3SL, 
100 mM 6SL with (15%, v/v) sterile caecum fluid in at 37°C for 16 h. Reaction products were 
separated by HPLC using a CarboPac PA200 column (Dionex) and detected by pulsed 
amperometry. The running conditions were 5 min of 100 mM NaOH for 5 min, followed by a 
linear gradient of sodium acetate from 0 to 250 mM over 40 min at a flow rate of 0.35 ml/min. 
The column was rinsed with 1 M sodium acetate for 5 min and equilibrated with 100 mM NaOH 
for 10 min. The retention times for lactose, sialic acid, 6SL, and 3SL were 4.7, 14.0, 22.0 and 22.4 
min respectively. Sialic acid concentration was determined by comparison of peak area with an 
authentic standard solution. 
 
Sialidase activity assay  
The recombinant B. vulgatus_4143 sialidase was expressed and purified as previously described. 
The fluorogenic substrate (4-MU-NeuNAc; Carbosynth) was used to determine sialidase activity. 
In brief, recombinant sialidase (ca. 0.25 μg) was incubated with 0.1 mM 4-MU-NeuNAc in 0.2 ml 
of 100 mM sodium acetate buffer (pH 7.4) at 37°C for 15 min. Assay was stopped by adding 0.8 
ml of 0.5 M sodium carbonate buffer (pH 10.5) and diluted 20-fold prior to fluorescence 
measurement at an excitation wavelength of 360 nm and an emission wavelength of 440 nm. 
2-O-(4-Nitrophenyl)-α-D-N-acetylneuraminic acid (pNP-NeuNAc; Carbosynth) was also used to 
determine the sialidase activity. Recombinant sialidase was incubated with 200 μM pNP-NeuNAc 
in 0.2 ml of 100 mM Tris-Cl buffer (pH 7.4) at 37°C for 2 h. Assay was stopped by adding 0.2 ml of 
0.4 M NaOH-glycine buffer (pH 10.8) and measured the absorption at 405nm with a microplate 
reader.  
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Abstract 
The gut microbiota plays critical roles in the establishment and maintenance of intestinal 
health. Imbalance of the gut microbiota is a hallmark of intestinal inflammation. In this study, 
we investigate the changes affecting the microbiota in wildtype and antibiotic-treated mice, 
and attempt to correlate altered microbial metabolism with the severity of colitis. We 
identify a reduction and imbalance of SCFAs in mice challenged by DSS or subjected to 
selective antibiotic treatments. In particular, the caecal levels of butyrate in mice inversely 
correlate with disease development. We also show that intestinal inflammation correlates 
with loss of butyrate-producing bacteria, such as Faecalibaterium prausnitzii and 
Eubacterium hallii. Moreover, the beneficial effect of butyrate enema on the severity of 
colitis suggests that butyrate administration represents a valid therapeutic approaches for 
the treatment of inflammatory bowel disease. 
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Introduction 
Inflammatory bowel disease (IBD), characterized by chronic inflammation of the 
gastrointestinal tract, is an emerging disease prevalent in developed countries. Of which, 
Crohn’s disease (CD) and ulcerative colitis (UC) are the most common types of IBD. It is 
widely accepted that IBD is caused by an inappropriate immune response against the gut 
microbiota in a genetically susceptible individuals [1]. Studies of human IBD patients and 
animal IBD models suggested that dramatic alterations of microbial composition in the 
intestine contribute to disease development. Although accumulating studies pointed to the 
potential role of gut microbiota in mediating IBD, no specific pathogenic bacterium could be 
directly assigned as cause of this disease. Nevertheless, increased Enterobacteriaceae and 
decreased in members of Clostridium cluster IV and XIVa are reproducibly documented in IBD 
patients [2]. For instance, a reduction of Faecalibacterium prausnitzii, a member of 
Clostridium cluster IV is repeatedly observed in patients with CD and is associated with a 
higher risk of recurrence disease [3-4]. The anti-inflammatory effects of F. prausnitzii have 
been associated with their production of short-chain fatty acids such as butyrate [3, 5].  
Butyrate, which is produced through bacterial fermentation of dietary carbohydrates in the 
intestine, exhibits a variety of functions in maintaining mucosal integrity and regulating 
immune responses [6]. Firstly, butyrate is a preferential energy source for colonocytes, 
mediating their proliferation and differentiation. Moreover, butyrate can strengthen the 
mucosal integrity by stimulating the production of mucins and antimicrobial peptides, and 
increasing the expression of tight junction proteins [6-7]. Notably, butyrate exerts a strong 
anti-inflammatory effect primarily through inhibition of histone deacetylase activity, resulting 
in a suppression of nuclear factor kappa B (NF-ƙB) activation and downstream 
pro-inflammatory signaling [8]. The multiple beneficial effects of butyrate on gastrointestinal 
physiology have made it an ideal candidate to treat IBD. Several clinical studies have revealed 
the beneficial effects of butyrate on attenuating intestinal inflammation in IBD patients 
[9-11]. However, a variety of other studies failed to show any clinical improvement [12-13] 
possibly because of differences in dosage, frequency, route and duration of administration. 
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Because of the low compliance in butyrate enema, administration of butyrate-producing 
bacteria enables the production of butyrate in situ, may become a potential treatment 
against IBD. Although microbial analysis has shown that the majority of butyrate-producing 
bacteria in human belong to Clostridial cluster IV and XIVa [14], the contribution of other 
butyrate-producing taxa is not fully elucidated. Therefore, we here investigate the 
interactions between gut microbiota, microbial metabolites, and the severity of colitis with 
the focus on identifying the roles of butyrate-producing species in a colitis model in mice.  
Results 
 
Antibiotics influence the severity of DSS-induced colitis in mice 
To investigate the contribution of intestinal microbiota to colitis development, we have 
altered the intestinal microbial composition by selective antibiotic treatment in both 
wildtype (WT) and sialyltransferases St3gal4
-/-
 (ST) mice. Mice were pre-treated with 
antibiotics for 3 weeks before being challenged with DSS to induce colitis. Vancomycin, 
neomycin and penicillin treatment exacerbated the severity of DSS-induced colitis in both 
WT and ST mice as shown by body weight loss compared to control group (Fig. 1a-c). By 
contrast, streptomycin treatment attenuated body weight loss (Fig. 1d). The protective effect 
of streptomycin towards DSS challenge was even more pronounced when streptomycin and 
DSS were administered in the same period in both WT and ST mice. Intestinal inflammation 
was further confirmed by measuring the colon length of antibiotic-treated mice. The 
shortening of colon length induced by DSS ingestion was aggravated by vancomycin, 
neomycin and penicillin, but unaffected by streptomycin (Fig. 1e). To exclude any damaging 
effect caused by the use of antibiotics on intestinal barrier, we have previously examined the 
intestinal epithelial permeability by measuring the leakage of FITC-dextran in the 
bloodstream [15]. Among all the antibiotic-treated group, we did not detect any significant 
damage on the intestinal barrier function. Taken together, these results confirmed the 
contribution of specific groups of bacteria in influencing the severity of intestinal 
inflammation. 
RESULTS 
 
114 
 
Effects of antibiotics on intestinal microbiota  
To determine whether exposure to antibiotic influenced specific groups of gut microbiota, 
we examined the microbial diversity from fecal samples of control and antibiotic-treated 
mice. The microbial compositional change was compared by denature gradient 
gel-electrophoresis (DGGE) of group specific bacterial 16S rDNA. The DGGE profiles revealed 
that bacterial composition of WT mice varied significantly among different antibiotic 
treatments. Of which, vancomycin and penicillin treatment promoted the outgrowth of 
Enterobacteriaceae spp. and Proteobacteria spp. but reduced the abundance unclassified 
Clostridial cluster IV and XIVa. These findings were confirmed by real-time PCR analysis 
targeting Clostridia cluster IV (Fig. 2a), Lachnospiraceae (cluster XIVa) (Fig. 2b), 
Ruminococcaceae (Fig. 2c), and Enterobacteriaceae (Fig. 2d). By comparison, streptomycin 
exhibited a minor effect to the major bacterial taxa family but dramatically reduced 
Enterobacteriaceae levels (Fig. 2d). Further analysis on bacterial genome suggested that E. 
coli accounted for the increased abundance of Enterobacteriaceae after vancomycin and 
penicillin treatment, which was consistent with our previous studies showing a positive 
correlation between the abundance of E. coli and the magnitude of inflammation [15].  
To better characterize bacterial change at the species level, we combined Bacteroidaceae- 
and Clostridial cluster-specific PCR and DGGE analysis. In this approach, we identified an 
ubiquitous presence of Bacteroides acidifaciens among control and all the antibiotic-treated 
groups, whereas Bacteroides vulgatus was only detected after antibiotic or DSS treatment 
but not in control mice (Supplementary Fig. 1). Moreover, Bacteroides uniformis and 
Parabacteroides distasonis were only identified in ST mice but not in WT mice 
(Supplementary Fig. 1). The anti-inflammatory effect of P. distasonis has been demonstrated 
in a recent study showing that some bacterial membrane component attenuated murine 
colitis via inhibiting TNF-α production, which may explain the better protection of ST mice 
against DSS-induced colitis [16]. However, we do not find strong correlations between the 
predominant bacterial families, such as Bacteroidaceae and Lactobacillaceae, and the 
magnitude of inflammation (Fig. 2e-f). Comparison studies on healthy subjects and IBD 
patients also yielded inconsistent results when associating major bacterial groups with 
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disease progression [17-18]. Therefore, to evaluate the functional impact of microbial change, 
we have also analyzed bacterial metabolites, thereby focusing on short-chain fatty acids 
(SCFAs), which are major fermentation products. 
 
Caecal SCFAs influence colitis in mice 
The levels of faecal SCFAs have been showed to be related with disease activity in human IBD. 
For instance, a significant reduction of butyrate was implicated with UC, whereas an increase 
of lactate correlated with diarrhea in UC patients [19]. Acetate and propionate were also 
found to be reduced in IBD compared to health individuals [20]. The anti-inflammatory 
properties of SCFAs have been demonstrated for butyrate and propionate, which induce the 
differentiation of TReg cells [21], and interact with G protein-coupled receptors to stimulate 
production of anti-inflammatory cytokines, such as IL-10 and TGF-β [22]. In this study, we 
found elevated levels of total caecal SCFAs in control WT mice compared to ST mice (Fig. 3a, 
Table 2). However, when mice were challenged by DSS, the reduction of caecal SCFAs were 
more evident in WT mice, suggesting an imbalance of gut bacteria during intestinal 
inflammation. By contrast, ST mice maintained relatively stable levels of SCFAs before and 
after DSS-induced colitis, indicating a minor microbial change. Moreover, the levels of caecal 
SCFAs decreased markedly among all the tested antibiotic treatment groups compared to the 
control group (Fig. 3b, Table 2). In particular, propionate and butyrate were completely 
absent in mice treated with vancomycin and penicillin, whereas lactate was increased 
compared to control mice, thus pointing to an inverse correlation between disease activity 
and the levels of SCFAs.  
In addition to the absolute amounts of caecal SCFAs, molar ratio between major SCFAs 
reflected the balance or dysbiosis of microbiota in the intestine. The molar ratio of caecal 
acetate: propionate: butyrate in WT mice (3.3: 1: 1) was similar to that of ST mice (3.3: 1.3: 
0.5) (Fig. 3c). However, when mice were challenged by DSS, the ratio of caecal SCFAs in 
WT-DSS mice skewed to 90: 9: 1 because of the significant decrease of butyrate production, 
whereas the ratio remained relatively stable in ST-DSS mice (5.9: 1.3: 1) (Fig. 3c). Imbalance 
of caecal SCFAs was also confirmed in antibiotic-treated model. WT mice treated with 
RESULTS 
 
116 
 
streptomycin showed stable levels of caecal SCFAs (3.1: 0.7: 1) and no significant impact on 
colitis development compared to control mice, whereas vancomycin- and penicillin-treated 
mice showed completed loss of caecal butyrate and propionate (Fig. 3d). Overall, the levels 
of caecal butyrate inversely correlated with colitis development, which underlined the 
significance of butyrate-producing bacteria in maintaining colonic health. 
 
Decreases of butyrate-producing bacteria in colitogenic mice 
Because the levels of caecal butyrate varied significantly in healthy and inflamed mice, we 
evaluated whether a reduction of butyrate relates to decreased levels of butyrate-producing 
bacteria in mice. Based on phylogenetic studies of human microbiome, we targeted the 
bacterial groups of Clostridial clusters IV and XIVa, which include most butyrate-producing 
bacteria [23]. By analyzing Clostridial-specific DGGE profiles, we found a complete loss of 
cluster IV Ruminococcus and Oscillibacter spp. in WT mice after vancomycin and penicillin 
treatment (Supplementary Fig. 2). In addition, faecal samples of ST mice revealed lower 
diversity of Ruminococcus such as R. bromii and R. champanellensis (Supplementary Fig. 2). 
However, Ruminococcus spp. have not been shown to produce butyrate. Therefore we 
targeted known butyrate-producing bacteria, including the species related to Eubacterium, 
Roseburia, Faecalibacterium and Coprococcus [23]. A profound decrease of Clostridial cluster 
XIVa spp. (Fig. 4a) and F. prausnitzii (Fig. 4b) in antibiotic- and DSS-treated WT mice, 
confirmed the positive correlation of these butyrate producers and caecal butyrate levels in 
mice. We also quantified the abundance of major butyrate producers, Roseburia spp. and 
Eubacterium hallii. We observed that Roseburia spp. was only detected in WT control mice 
but not any other antibiotic-treated WT mice and ST mice (Fig. 4c). The exclusive presence of 
Roseburia spp. in WT mice may explain the high caecal butyrate levels detected in WT mice, 
since these bacteria are considered to be as major butyrate producer [23]. By contrast, E. 
hallii was only identified in ST and DSS-treated ST mice but not in WT mice (Fig. 4d), 
suggesting that this bacterium may contribute to the residual butyrate production (mean 
butyrate levels in ST mice: 9.3 mM; ST-DSS: 8.4 mM; WT-DSS: 0.4 mM) in ST mice, and that 
their abundance correlated with reduced inflammation in ST mice. Overall, our results 
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showed that intestinal inflammation matched with lower levels of mucosal 
butyrate-producing bacteria, particularly F. prausnitzii and E. hallii. The results were also 
consistent with recent studies indicating that altered mucosal layer and dysbiosis may impair 
the colonization fitness of these butyrate producers and further influence butyrate 
metabolism in the gut [3, 24]. 
 
Butyrate administration attenuates intestinal inflammation 
The impact of butyrate on colonic health underlines its beneficial role against IBD. However, 
the delivery model of butyrate to particular colon regions remains problematic. Therefore, 
we compared the therapeutic effect of butyrate via different delivery modes in murine 
DSS-induced colitis model. Firstly, WT mice were orally supplemented with 100 mM sodium 
butyrate in drinking water for 7 days, during which they also challenged by DSS on the first 5 
days. The water consumption and disease activity was monitored daily. WT mice treated in 
such a way with sodium butyrate showed no significant change of body weight compared to 
control mice treated with sterile water (Fig. 5a). A similar outcome was also observed in ST 
mice (Fig. 5b). In contrast to dietary butyrate-containing fibers which are slowly released 
along the gastrointestinal tract, solute sodium butyrate is directly available and immediately 
absorbed in the upper digestive tract before reaching the colon [7], which suggests that oral 
supplementation of butyrate salt may be impractical for clinical treatment. Next, we 
evaluated the effects of butyrate enema on attenuating intestinal inflammation by rectal 
administration of butyrate-containing saline during DSS-induced colitis. Mice treated with 
butyrate enema showed a reduced loss of body weight in the initial phase of colitis, but 
without reaching any significant improvement in the late-stage of colitis (Fig. 5c). This limited 
efficacy may be explained by the short-term effect of butyrate enema (only once per day 
until day 4) as well as a discontinuous butyrate exposure of the colon. Nevertheless, the 
amelioration of the inflammation and symptoms such as reduced the shortening of colon 
(Fig. 5d), and decreased bleeding (data not shown) strongly suggested the protective role of 
butyrate against colitis. Taken together, our results showed that butyrate enema has 
therapeutic effects, at least in part, against DSS-induced colitis. Further investigation should 
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be focus on improving the regimen, such as dosage, frequency, and duration as well as 
evaluating the capability of butyrate-producing bacteria, such as F. prausnitzii and E. hallii 
identified in this study, on ameliorating colitis.  
 
Discussion 
In the present study, we showed a significant reduction among members of the Clostridial 
cluster IV and XIVa in faecal samples of colitogenic mice during intestinal inflammation. In 
particular, the reduction of predominant butyrate producers including F. prausnitzii, 
Roseburia spp., and E. hallii in colitogenic mice correlated with the decreased levels of 
butyrate and the disease activity. Finally, we showed that exogenous supply of butyrate 
attenuated intestinal inflammation in murine colitis model, suggesting its protective effect 
against colitis. 
 
SCFAs are organic fatty acids derived from bacterial fermentation of carbohydrates, dietary 
fibers, and proteins in the colon. Fermentation process provides energy for microbial growth 
as well as other metabolites for use by the host. The metabolism of colonic SCFAs was mainly 
dependent on the availability of fermentable diet and the composition of gut microbiota. In 
healthy subjects, the production of acetate: propionate: butyrate is approximately in a molar 
ratio of 60: 20: 20, respectively [25], and such ratio is relatively stable along the colon in the 
conditions of gut homeostasis. Our SCFAs analysis showed that the average molar ratio of 
main SCFAs (3.3: 1: 1), and caecal butyrate levels (range: 10-40 mM) in WT mice was very 
similar to healthy individuals (ratio 3: 1: 1; butyrate range: 11-25 mM) [26], indicating that 
regulation of butyrate metabolism is fairly constant. However, the levels of colonic SCFAs 
cannot represent the in situ production of total SCFAs, since more than 95% of the SCFAs, 
especially butyrate, are rapidly absorbed and metabolized by the host [27]. Moreover, the 
estimated amount of total SCFAs decreased from proximal colon (range: 70-140 mM) to the 
distal colon (range: 20-70 mM) [28].This suggests the levels of SCFAs likely also reflect the 
relative absorption capability by colonic enterocytes Consequently, the considerable 
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imbalance and reduction of colonic SCFAs is indeed a diagnostic parameter to monitor 
chronic inflammation caused by microbial dysbiosis and impaired colonic epithelium. 
 
Butyrate is produced mainly via butyryl-CoA: acetate CoA transferase enzyme, or less 
frequently by butyrate kinase [29]. Bacteria that utilize butyryl-CoA: acetate CoA transferase 
include several Clostridial cluster IV and XIVa species, such as F. prausnitzii, Roseburia spp., 
Eubacterium and Butyricicoccus spp. which generally convert acetate to butyrate. E. hallii can 
also use lactate to produce butyrate, thus have an important role in stabilizing the intestinal 
microenvironment by preventing the accumulation of lactate [14, 30]. Several studies have 
reproducibly documented a decrease of butyrate producers, especially F. prausnitzii, and 
more recently Roseburia hominis in the gut of IBD patients [5], suggesting a positive probiotic 
effect of such bacteria for treatment of IBD. In addition, a recent study showed that 
Butyricicoccus bacteria, which exerts anti-inflammatory properties, were significantly lower 
in the gut of IBD patients than healthy subjects. Administration of Butyricicoccus bacteria 
also attenuated experimental colitis in rat by decreasing production of inflammatory 
cytokines [31]. Our data suggested that lower abundance of E. hallii and F. prausnitzii 
correlates with the disease activity. Accordingly, their presence in ST mice may account for 
the residual butyrate production detected in these mice during inflammation. Overall, 
butyrate-producing bacteria present in the colon are phylogenetically diverse. Therefore, 
further isolation and culture of targeted bacteria will be necessary to elucidate the function 
of butyrate producers and their interplay between diet and other microbiota. 
 
The critical roles of butyrate on maintaining colonic health prompted researchers to examine 
their therapeutic effects against intestinal inflammation. SCFA enemas, especially butyrate, 
are mostly applied and demonstrated a marked improvement in treating bowel disease 
[10-11]. However, some studies also revealed inconsistent clinical outcomes [12, 32], possibly 
due to the variation of dosage, frequency and duration of treatments. Moreover, a low 
compliance rate and discontinuous applications also limited the efficacy of SCFA enema. 
Therefore, the use of encapsulated organic acids and oral ingestion of fermentable dietary 
fibers have been explored. Lipid-encapsulated butyrate shows a promise of treating bowel 
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disease by slowly and continuously release the active components along the whole 
gastrointestinal tract or targeted release the components in the specific region [33]. 
Fermentable fibers such as germinated barley [34], inulin [35], and oat bran [36] have also 
been investigated in several clinical studies and shown to increase faecal SCFAs levels and 
prolonged remission in IBD patients [37]. These studies help to provide the dietary 
recommendations for supporting colonic health and disease prevention. Further longitudinal 
analysis of microbiota composition and functional analysis of the microbial metabolism in a 
large cohort of IBD patients will help to develop the treatment for IBD. 
 
Materials and Methods 
Real-time PCR analysis of microbial 16S rDNA 
The abundance of bacterial family and genera in fecal samples was determined by real-time 
PCR using the EvaGreen qPCR Master Mix (Biotium). Primer pairs specific for 16S rDNA of 
Bacteroidaceae (Bac32F, Bac303R), Lachnospiraceae (Erec482F, Erec870R) Lactobacillaceae 
(Lacto-05, Lacto-04), Enterobacteriaceae (Eco1457F, Eco1652R), Clostridia Cluster IV 
(Clep866mF, Clept1240mR), Ruminococcaceae (Rflbr730F, Clep866mR), and total bacteria 
(Eub338F, Eub518R) were described previously [38-39]. Cycling conditions were 40 cycles at 
95°C for 10 s, annealing for 10 s and 72°C for 25 s after an initial denaturation at 95°C for 3 
min. The annealing temperature for each primer pair is listed in table 1. Quantification values 
were calculated by the 2
-△Ct
 method relative to total bacterial 16S rDNA amplicons. To 
determine the relative abundance of butyrate-producing bacteria, primers 
targeting Faecalibacterium prausnitzii (FPR-2F, Fprau645R)[3], Roseburia spp (RrecF, RrecR) 
and Eubacterium hallii (EhalF, EhalR)[40] were used and quantified by the 2
-△Ct method 
relative to total bacterial 16S rDNA [41]. 
 
Mouse models and DSS-induced colitis 
Conventionally reared C57BL/6 wildtype and sialyltransferase St3gal4
 
knockout mice were 
derived from the same breed and maintained in light-cycled and climate-controlled facility. 
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All experiments were performed in compliance with the Swiss Animal Protection Ordinance 
and approved by the Veterinary Office of the Canton of Zurich, Switzerland. For DSS-induced 
colitis, 6-7 week-old, gender-matched mice were treated with 3- 3.5% (w/v) of DSS 
(MW=36-50 kDa; MP Biomedicals) in drinking water for 5 days, followed by a supply of 
normal water until sacrifice of the animals. Body weight and physical activity were monitored 
daily. For antibiotic treatment, 3-week-old mice were provided with sterile drinking water 
supplemented with vancomycin (0.5 g L
-1
), streptomycin (1 g L
-1
), neomycin (1 g L
-1
), or 
penicillin (0.5 g L
-1
) plus aspartame (0.25%, w/v) for 3 weeks before DSS treatment. 
 
Heteroduplex DNA amplification 
Mouse fecal DNA was isolated from stool samples using the QIAamp DNA Stool Mini Kit 
(Qiagen) according to manufacturer’s instructions. Lysis temperature was increased to 95°C 
for 5 min to ensure complete cell lysis of Gram-positive bacteria. Extracted DNA were 
subjected to PCR using the 16S rDNA universal heteroduplex analysis (HDA) primers 
HDA1-GC and HDA2 [42], U968-GC and L1401r [43], Bac32GC-f, and Bac303-r [44]. GC clamp 
was attached at the 5’ end of wither forward or reverse primer. Additional primers used for 
specific bacterial group amplification are listed in table 1. PCR conditions were 5 min of initial 
denaturation, followed by 30 cycles of 30 s at 95
 o
C, 30 s at 56
 o
C and 1 min at 72 
o
C, and the 
final elongation at 72 
o
C for 5 min. PCR products were verified by agarose gel electrophoresis 
before being subjected to DGGE analysis. 
 
Denaturing gradient gel electrophoresis (DGGE)  
The amplified 16S rDNA products were subjected to DGGEusing an INGENYphorU (Ingeny 
International BV) system as previously described [45]. In brief, the system was equipped with 
a 4.5% of polyacrylamide gel with denaturant in the range of 40-60%, in which 100% 
denaturant is equivalent to 7M of urea and 40% of formamide. Electrophoresis was carried 
out at 130 V for 7 h at 58 
o
C. Polyacrylamide gel was stained with GelRed nucleic acid stain 
(Biotium) for 30 min, destained in distilled water and viewed under UV light. DNA bands of 
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interest were excised, and resuspended in ultrapure water at 4 
o
C overnight. The extracted 
DNA was reamplified using the same primer and PCR conditions. To purify the bacterial DNA, 
products were reloaded on a denaturant gradient and separated before being subjected to  
reamplification using the same PCR conditions. The DNA product was purified using 
NucleoSpin gel purification kit (Macherey-Nagel, Germany) before sequencing (Microsynth, 
Switzerland). Bacterial taxonomy was assigned using the Ribosomal database Project (RDP) 
classifier [46]. 
 
Quantitative analysis of caecal SCFA 
Mouse caecal contents were isolated and centrifuge at 4°C and 15,000 x g for 10 min. The 
supernatant was diluted with ultrapure water and filtered through a 0.45 μm nylon filter 
(Infochroma AG), and stored in -80°C before analysis. SCFA analysis was performed by HPLC 
using cation-H refill cartridge (30 x 4.6 mm) and Aminex® HPX-87H column at a flow rate of 
0.4 ml min
-1
 for 60 min and eluted with 10 mM sulphuric acid solution [47] . Quantification 
was done by refractive index detection. Each sample runs in duplicate, and the concentration 
(mM) was calculated by integral area comparison with authentic standard solutions.  
 
Butyrate supplementation in mice  
For oral supplementation, 7-week old WT and ST male mice received a SCFA mixture in 
drinking water containing 100 mM sodium butyrate (Sigma-aldrich) plus 0.25% sweetener for 
7 days together with 2.5-3 % DSS for the first 5 days. Control mice received normal drinking 
water and DSS. For rectal administration, 7-week old WT male mice were administered 
sterile sodium butyrate solution and challenged with 3% DSS for 5 days. Mice were mildly 
anesthetized by isoflurane inhalation and received rectal instillation of 100 μl of sterile PBS 
or 100 mM sodium butyrate by polyethylene catheter PE-50 (Becton Dickson, New Jersey). 
Both solutions were adjusted to pH 6.5. Mice were kept in a vertical position head-down for 
2 min to avoid excretion of the enema solution. After rectal administration, body weight and 
sign of the dehydration were monitored for the duration of the experiment. 
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Statistical analysis 
Statistical analysis was performed using the GraphPad Prism 5.0 software (San Diego, CA). 
The results were tested by two-tailed unpaired Student’s t-test and ANOVA Bonferroni 
multiple comparison test. Difference reaching P values below 0.05 were considered 
significant. Results are presented as mean ± SEM unless specified.  
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Table 1. Primer list of quantitative microbial analysis and DGGE profiling 
Primers for quantitative microbial analysis 
Bacteria  Primers Sequences 5’-3’ Size (bp) Anneal (
o
C) 
Bacteroidetes Bac32F 
Bac303R 
AACGCTAGCTACAGGCTT 
CCAATGTGGGGGACCTTC 
276 55 
Clostridia Cluster 
IV 
Clep866F 
Clept1240
R 
TTAACACAATAAGTWATCCACCTGG 
ACCTTCCTCCGTTTTGTCAAC 
314 64 
Enterobacteriace
ae 
Eco1457F 
Eco1652R 
CATTGACGTTACCCGCAGAAGAAGC 
CTCTACGAGACTCAAGCTTGC 
195 62 
Lactobacillaceae F_Lacto 05 
Lacto 04 
AGCAGTAGGGAATCTTCC 
CGCCACTGGTGTTCYTCCATATA 
383 66 
Lachnospiraceae  Erec482F 
Erec870R 
CGGTACCTGACTAAGAAGC 
AGTTTYATTCTTGCGAACG 
429 55 
Ruminococcaceae Rflbr730F 
Clep866m
R 
GGCGGCYTRCTGGGCTTT 
CCAGGTGGATWACTTATTGTGTTAA 
157 60 
F. prausinitzii FPR-2F 
Fprau645R 
GGAGGAAGAAGGTCTTCGG 
AATTCCGCCTACCTCTGCACT 
248 58 
Roseburia spp 
 
RrecF 
RrecR 
GCGGTRCGGCAAGTCTGA 
CCTCCGACACTCTAGTMCGAC 
81 60 
Eubacterium 
hallii 
EhalF 
EhalR 
GCGTAGGTGGCAGTGCAA 
GCACCGRAGCCTATACGG 
 
276 60 
Primers for DGGE profiling 
Universal 16S 
(V3) 
HDA1-GC 
HDA2 
GC-clamp + 
ATCCCTACGGGAGGCAGCAGT 
GTATTACCGCGGCTGCTGGCA 
200 56 
Universal 16S 
(V6-V8) 
U968-GC 
L1401r 
GC-clamp + ACGCGAAGAACCTTAC 
GCGTGTGTACAAGACCC 
430 56 
Clostridia cluster 
IV 
Clep-F 
GC-Clep-R
3 
GCACAAGCAGTGGAGT 
GC-clamp + 
CTTCCTCCGTTTTGTCAA 
239 55 
Bacteroida- ceae Bac32-GC 
Bac303r 
GC-clamp + 
AACGCTAGCTACAGGCTT 
CCAATGTGGGGGACCTTC 
276 53 
GC clamp: CGCCCGGGGCGCGCCCCGGGCGGGGCGGGGGC ACGGGGGG 
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Table 2. Levels of SCFAs in caecal samples of WT and ST mice 
Conc (mM) WT   ST 
Treatment Ctrl Stp Van Pen DSS  Ctrl DSS 
Acetate 80.2 ± 4.4 
a
 23.1 ± 3.5 
b
 12.8 ± 5.4
 b
 7.9 ± 0.7
 b
 25.7 ± 2.1 
b
 
 
61.6 ± 3.0 
a
 48.3 ± 3.6 
b
 
Propionate 24.7 ± 1.9 
a
 5.5 ± 0.8 
b
 1.2 ± 1.0 
c
 0.2 ± 0.2
 c
 2.9 ± 1.1 
c
 
 
24.3 ± 2.0 
a
 11.0 ± 1.9 
b
 
Butyrate 24.1 ± 2.6 
a
 7.7 ± 1.0 
b
 0.2 ± 0.2
 c
 0.2 ± 0.2
 c
 0.4 ± 0.3 
c
 
 
9.3 ± 0.8 
a
 8.4 ± 1.0 
a
 
Lactate 10.8 ± 0.4 
a
 3.0 ± 0.3 
b
 9.5 ± 1.6 
a
 8.5 ± 1.3 
a
 14.9 ± 1.6 
a
 
 
9.1 ± 0.9 
a
 11.2 ± 2.5 
a
 
SCFAs, short-chain fatty acids. The data is represented as the mean ± SEM from two independent experiments, 
N=6-8. Different letters in the same row indicate which treatments are statistically significant (p <0.05, ANOVA 
multiple Bonferroni multiple comparison test) 
 
Figure legends 
 
Figure 1. Antibiotic effects on DSS-induced colitis. 7-week-old gender-matched WT and ST 
mice were challenged with DSS (3.3%, w/v) in drinking water for 5 days, followed by a supply 
of normal drinking water until sacrifice of the animals. For antibiotic treatment, mice were 
treated with (a) 1 g L
-1 
neomycin (Neo), (b) 0.5 g L
-1
 vancomycin (Van), (c) 0.5 g L
-1
 penicillin 
(Pen) or (d) 1 g L
-1
 streptomycin (Stp) for 3 weeks before DSS challenge. Control mice 
received normal drinking water and DSS. Body weight and physical activity were monitored 
daily. (e) Colon length was measured at day 7 after initiation of DSS challenge and given as 
percentage to the colon length of mice without any treatment. The data is represented as 
mean ± SEM, N=6-8. The letters above the bars indicate which treatments are statistically 
significant (p <0.05, ANOVA Bonferroni multiple comparison test). 
 
Figure 2. Antibiotic effects on the intestinal microbiota. The compositions of the intestinal 
microbiota of control and antibiotic-treated mice were determined by real-time PCR 
targeting specific 16S rDNA bacterial phylogenetic groups. The relative abundance of (a) 
Clostridia cluster IV (b) Clostridia cluster XIVa (Lachnospiraceae) (c) Ruminococcaceae (d) 
Enterobacteriaceae (e) Bacteroidaceae, and (f) Lactobacillaceae was quantified using 2
-△Ct
 
method to the total bacteria 16S rDNA. The data is represented as median from two 
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independent experiments, N=5-7. Statistical difference versus control group *p <0.05, 
(ANOVA Bonferroni multiple comparison test). 
 
Figure 3. Quantitative analysis of caecal SCFAs. At day 7 after initiation of DSS treatment, 
mice caecal fluid was collected. The levels of SCFAs in caecal fluid were analyzed by HPLC. (a) 
The concentrations of acetate, propionate, butyrate and lactate were calculated by 
comparing to the authentic standard solution. Each sample runs in duplicate and the data is 
represented as mean ± SEM from three independent experiments, N=15. (b) Caecal fluid 
samples from control and antibiotic-treated WT mice were collected. The levels of SCFAs and 
lactate were analyzed by HPLC. Dta is represented as mean ± SEM, N=6-8. The letters above 
the bars indicate which treatments are statistically significant (p <0.05, ANOVA multiple 
Bonferroni multiple comparison test). (c) The molar ratio of caecal SCFAs in WT and ST mice, 
and (d) antibiotic-treated WT mice was given as percentage of total SCFAs obtained from a 
pool of 6 mice per group. 
 
Figure 4. Quantitative analysis of butyrate-producing bacteria. Relative abundance of 
butyrate-producing bacteria in mice was determined by real-time PCR using specific 16S 
rDNA primers targeting (a) Clostridial XIVa (b) F. prausnitzii (c) Roseburia spp and (d) 
Eubacterium hallii, and quantified by the 2
-△Ct
 method. A group of 6-7 week-old WT and ST 
mice were treated with or without DSS for 5 days. For antibiotic treatment, WT mice were 
treated streptomycin (Stp 1 g L
-1
) or vancomycin (Van 0.5 g L
-1
) for 3 weeks. The data is 
represented as median values. Each point indicates an individual mouse from two 
independent experiments, N=6-7, statistically significant versus WT control group, *p value < 
0.05 (ANOVA multiple Bonferroni multiple comparison test). 
 
Figure 5. The effects of butyrate administration to mice in DSS-induced colitis. (a) WT mice 
were treated with 100 mM of butyrate in drinking water for 7 days, and challenged with 2.5% 
DSS for the initial 5 days. Body weight was monitored daily. (b) ST mice were treated with 
100 mM of butyrate in drinking water for 7 days, and challenged with 3% DSS for the initial 5 
days. Control mice received drinking water and DSS. The data is represented as mean ± SEM, 
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N=5. (c) WT mice were rectally administered with 100 mM sterile sodium butyrate or PBS at 
time points marked with black arrows and challenged by 3% of DSS in drinking water. (d) 
colon length was measured at day 7 after initiation of DSS challenge. The data is represented 
as mean ± SEM, N= 4-6. ns, not significant (two-tailed Student’s t test). 
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Figure 1 
 
 
  
c 
a b 
50
60
70
80
90
100
110
DSS    -   +   +   +    +   +
Abx  -     -   Stp Neo Van Pen
-   +   +   +    +   +
-     -   Stp Neo Van Pen
WT ST
a a
b b
c c c
b b b
c c
Co
lo
n
 
len
gt
h 
 
(%
)
e 
d 
0 1 2 3 4 5 6 7 870
75
80
85
90
95
100
105
110
ST
WT
WT-Stp
ST-Stp
Time (days)
Bo
dy
 
w
ei
gh
t (%
)
0 1 2 3 4 5 6 7 870
75
80
85
90
95
100
105
110
ST
WT
WT-Pen
ST-Pen
Time (days)
Bo
dy
 
w
ei
gh
t (%
)
0 1 2 3 4 5 6 7 870
75
80
85
90
95
100
105
110
ST
WT
WT-Van
ST-Van
Time (days)
Bo
dy
 
w
ei
gh
t (%
)
0 1 2 3 4 5 6 7 870
75
80
85
90
95
100
105
110
ST
WT
WT-Neo
ST-Neo
Time (days)
Bo
dy
 
w
ei
gh
t (%
)
RESULTS 
 
132 
 
Figure 2 
 
  
Lactobacillaceae
Ctrl Stp Neo Van Pen
10 - 8
10 - 7
10 - 6
10 - 5
10 - 4
10 - 3
10 - 2
10 - 1
100
Re
lat
ive
La
to
ba
ci
lla
ce
ae
16
S 
rD
NA
 
to
 
to
ta
l b
ac
te
ria
l
f 
d 
b 
Enterobacteriaceae
Ctrl Stp Neo Van Pen
10 - 8
10 - 7
10 - 6
10 - 5
10 - 4
10 - 3
10 - 2
10 - 1
100
Re
lat
ive
En
te
ro
ba
ct
er
ia
ce
a
e
16
S 
rD
NA
 
to
 
to
ta
l b
ac
te
ria
l
*
*
Clostridia cluster (XIVa)
Ctrl Stp Neo Van Pen
10 - 8
10 - 7
10 - 6
10 - 5
10 - 4
10 - 3
10 - 2
10 - 1
100
*
*
*
Re
la
tiv
e
Cl
o
st
rid
ia
 
XI
Va
16
S 
rD
NA
 
to
 
to
ta
l b
ac
te
ria
l
e 
c 
a 
Ruminococcaceae
Ctrl Stp Neo Van Pen
10 - 8
10 - 7
10 - 6
10 - 5
10 - 4
10 - 3
10 - 2
10 - 1
100
Re
la
tiv
e
R
u
m
in
oc
o
cc
a
ce
a
e
16
S 
rD
NA
 
to
 
to
ta
l b
ac
te
ria
l
* *
Bacteroidaceae
Ctrl Stp Neo Van Pen
10 - 8
10 - 7
10 - 6
10 - 5
10 - 4
10 - 3
10 - 2
10 - 1
100 *
*
*
Re
lat
ive
Ba
ct
e
ro
id
a
ce
a
e
16
S 
rD
NA
 
to
 
to
ta
l b
ac
te
ria
l
Clostridia cluster IV
Ctrl Stp Neo Van Pen
10 - 8
10 - 7
10 - 6
10 - 5
10 - 4
10 - 3
10 - 2
10 - 1
100
Re
lat
ive
Cl
os
tri
di
a 
IV
16
S 
rD
NA
 
to
 
to
ta
l b
ac
te
ria
l
* *
RESULTS 
 
133 
 
Figure 3 
 
  
a 
d 
C Stp Va
n
Pe
n
0
25
50
75
100
Acetate
Propionate
Butyrate
SC
FA
 
re
lat
ive
 
pe
rc
en
ta
ge
c 
WT
WT
-
DS
S ST
ST
-
DS
S
0
25
50
75
100
Acetate
Propionate
Butyrate
SC
FA
 
re
la
tiv
e 
pe
rc
en
ta
ge
C Stp Va
n
Pe
n C Stp Va
n
Pe
n C Stp Va
n
Pe
n
0
10
20
30
50
75
100
Acetate Propionate Butyrate
a
b b b
b
c c
b
a a
WT
Abx
c c
Ca
ec
al 
fe
rm
en
ta
tio
n 
pr
od
uc
ts
co
nc
en
tra
tio
n 
(m
M)
b 
0
10
20
30
40
50
75
100
WT
ST
DSS    -     -    +    +         -    -    +    +         -    -     +    +
Acetate Propionate
a
a a
b a a
b
c
a
b b
c
Butyrate
Ca
ec
al 
fe
rm
en
ta
tio
n 
pr
od
uc
ts
co
nc
en
tra
tio
n 
(m
M)
RESULTS 
 
134 
 
Figure 4  
 
 
 
  
b a 
d 
C DSS Stp Van C DSS
10 - 8
10 - 7
10 - 6
10 - 5
10 - 4
10 - 3
*
WT ST
*
Re
la
tiv
e 
E.
 
ha
llii
 
to
 
to
ta
l b
ac
te
ria
l D
NA
 
(2-
∆ C
t )
C DSS Stp Van C DSS
10 - 8
10 - 7
10 - 6
10 - 5
10 - 4
10 - 3
WT ST
* * *
Re
lat
ive
 
F.
 
pr
au
sn
itz
ii
 
to
 
to
ta
l b
ac
te
ria
l D
NA
 
(2-
∆ C
t )
C DSS Stp Van C DSS
10 - 8
10 - 7
10 - 6
10 - 5
10 - 4
10 - 3
*
WT ST
* * * *
Re
la
tiv
e 
Ro
se
bu
ria
 
sp
p
 
to
 
to
ta
l b
ac
te
ria
l D
NA
 
(2-
∆ C
t )
C DSS Stp Van C DSS
10 - 8
10 - 7
10 - 6
10 - 5
10 - 4
10 - 3
10 - 2
10 - 1
100
WT ST
* * *
Re
la
tiv
e 
Cl
os
tri
di
al
 
XI
Va
 
to
 
to
ta
l b
ac
te
ria
l D
NA
 
(2-
∆ C
t )
c 
RESULTS 
 
135 
 
Figure 5 
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Supplementary Figure 1. Effects of 
antibiotic to the diversity of gut 
microbiota. DGGE profiles of bacterial 
16S rDNA amplified from fecal DNA of 
antibiotic-treated WT mice (upper 
panel) and ST mice (lower panel). The 
bacterial 16S rDNA was amplified by 
specific primer targeting for the 
Clostridia cluster IV group. Each lane 
represents DNA of fecal bacteria from 
individual mouse. Horizontal box mark 
the position of a corresponding member 
of Ruminococcaceae spp (R1: R. bromii, 
R3: R. bromii, R4: Oscillibacter spp., R7: 
R. callidus, R8: Oscillibacter spp., R10: R. 
champanellensis, M: marker) 
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Supplementary Figure 2. Effects of 
antibiotic to the diversity of gut 
microbiota. DGGE profiles of bacterial 16S 
rDNA amplified from fecal DNA of 
antibiotic-treated WT mice (upper panel) 
and ST mice (lower panel). The bacterial 
16S rDNA was amplified by specific primer 
targeting for the Bacteroidetes group. Each 
lane represents DNA of fecal bacteria from 
individual mouse. Horizontal box mark the 
position of a corresponding member of 
Bacteroidaceae spp. (B1.0-B1.2: B. 
acidifaciens, B2: B. vulgatus, B3: B. 
uniformis, B4, Porphyromonadaceae spp., 
B5: Parabacteroides distasonis, B6: 
Prevotellaceae spp. M: marker) 
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Supplementary Figure 3. Effects of 
antibiotic to the diversity of gut 
microbiota. DGGE profiles of bacterial 16S 
rDNA amplified from fecal DNA of WT mice 
and ST mice. The bacterial 16S rDNA was 
amplified by universal primer (U968GC and 
L1401r). Each lane represents DNA of fecal 
bacteria from individual mouse. Horizontal 
box mark the position of a corresponding 
bacterium. (A2: Segmented filamentous 
bacteria, A3: Ruminococcus gauvreauii, A4: 
Clostridium spp., A5: Clostridium spp., A6: 
Ruminococcus spp. A8: Butyrate-producing 
bacteria, M: marker) 
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GENERAL DISCUSSION 
Several recent studies have reported that intestinal inflammatory diseases are frequently 
accompanied by microbial dysbiosis and impaired mucosal functions. However, the 
mechanisms underlying such changes remain largely unknown. Dietary carbohydrates are a 
major source of nutrients that profoundly affect the gut microbiota. The impact of complex 
carbohydrates on microbial composition is based on the production of specific hydrolases, 
which enable some bacterial species to utilize the breakdown products as nutrients, thereby 
conferring a growth advantage over bacteria that cannot process complex glycans. We 
showed that sialic acids provided by milk oligosaccharides and released from host mucosal 
tissues confers a proliferative advantage for E. coli during lactation and intestinal 
inflammation. Moreover, we identified an increased availability of intestinal sialic acids 
during inflammation was mediated by Bacteroides vulgatus-derived sialidase, which enables 
the sialic acid-dependent proliferation of E. coli during inflammation. By application of an 
nanT mutant E. coli strain and the inhibition of sialidase, we confirmed the essential 
contribution of sialic acid catabolism on promoting microbial dysbiosis as manifested by E. 
coli expansion. 
 
The role of glycosylation in mucosal immunity 
 
Mucosal surface is covered with a thick layer of mucus that is decorated by a considerable 
amount of glycans. Decreased glycosylation on mucins has been documented in patients 
with IBD, suggesting an increased mucosal exposure to bacteria and may potentially trigger 
inflammation [1]. Given the richness of sialylation on intestinal mucins, a variety of bacteria 
and viruses has targeted the host-derived sialylated glycans for adhesion, degradation and 
infection. Many commensal and pathogenic bacteria have been shown to secret sialidases 
which release free sialic acids from the mucosa[2]. The extracellular sialidases not only 
enhance bacterial survival through nutritional benefit but also increase bacterial adhesion by 
unmasking the underlying cryptic ligands [3]. Moreover, the sequential degradation of 
mucosal glycans by bacterial glycosidases requires the initial removal of sialic acids before 
further digestion. This explains an increasing sialic acid gradient from ileum to colon as a 
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mechanism to separate the underlying mucosal epithelium from a tremendous amount of 
mucin-degrading bacteria and extracellular glycosidases in the colon [4]. Structural analysis 
on mucosal sialoglycans reveals other sialic acid derivatives, such as mono- and di- 
O-acetylated sialic acids, which are also prevalent in human. The O-acetylation of sialic acids 
has been shown to significantly inhibit the rate of sialic acids cleavage by bacterial sialidases, 
therefore reinforces the protection from bacterial degradation. However, intestinal bacteria 
respond by producing sialate O-acetylesterase that removes the O-acetylation (carboxylic 
ester group) of sialic acids [5]. The subsequent removal of O-acetylation on sialic acids 
facilitates the degradation of sialoglycans by sialidases, suggesting the role of sialate 
O-acetylesterase on regulating sialic acid metabolism.  
 
Our proteomic analysis of microbial glycosidases also identified a bacterial-derived sialate 
O-acetylesterase in the caecal fluid of colitogenic mice. This finding was consistent to a 
previous study showing that an increased sialate O-acetylesterase activity was observed in 
the fecal extract of UC patients [6], and later confirmed the enzyme activity in E. coli K1 
strain [7]. Interestingly, by fluorometric-HPLC analysis of caecal sialic acids and their 
derivatives from mice, we identified high levels of O-acetylated sialic acid (Neu5,9Ac2) and 
low levels of Neu5Gc. However, whether these sialic acid derivatives also confer a 
proliferative advantage to E. coli during inflammation, and whether the release of sialic acid 
derivatives requires different sialidases remains to be investigated. Collectively, 
bacterial-producing sialidases and sialate O-acetylesterase both show profound effects on 
mediating sialic acids catabolism and hence regulate the sialic acid-dependent proliferation 
of bacteria. 
 
Recent meta-analysis of genome-wide association studies have identified more than 
hundreds of genetic susceptible loci that are linked to IBD pathogenesis [8-9]. These studies 
highlight the importance of epithelial barrier functions, innate receptors, ER stress, and 
autophagy in the pathogenesis of IBD. Of particular interest, the loss-of-function alleles of 
the α1,2-fucosyltransferase FUT2 gene and single nucleotide polymorphisms are strongly 
associated with CD pathogenesis [10]. Fucosyltransferase 2, which regulates mucosal 
expression of ABO blood group antigens, has been shown to maintain the integrity of 
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epithelial barrier, thereby influenced host-microbiota interaction [11]. Studies on FUT2 
deficient mice also showed an increased susceptibility to the development of chronic 
inflammation [12], and studies on FUT1 gene polymorphisms showed an increased 
susceptibility to fimbriated E. coli adhesion and infection [13]. Moreover, innate immunity is 
also involved in the regulation of mucosal fucosylation. A recent study has described 
systemic exposure to TLR-ligands leads to a rapid α1,2-fucosylation of intestinal epithelial 
cells driven by IL-22. The nature of intestinal fucosylation seems to be a protective 
mechanism to maintain the balance between host immune response and microbiota during 
bacterial infection [14]. Of note, our study also identified a robust fucosidase activity in the 
caecal fluid of mice, therefore bacterial-derived fucosidase is also likely to play a potential 
role in digestion of mucosal glycans and mediating the intestinal inflammation. Accordingly, it 
is interesting to address whether intestinal sialylation also responds similarly to the bacterial 
and environmental stimuli. Besides fucosylation and sialylation on mucosal glycans, the 
importance of mucin O-glycosylation has also been demonstrated in several 
glycosyltransferases-deficient mice models, in which impaired mucin O-glycosylations on 
core 1, 2, and 3 structures increased the susceptibility to colitis in mice [15-17]. 
 
For the treatment of microbial dysbiosis and intestinal inflammation, we showed that daily 
administration of the sialidase inhibitor, Neu5Ac2en, effectively inhibits the intestinal 
sialidase activity and reduces E. coli expansion in mice, whereas other neuraminidase 
inhibitors, zanamivir and oseltamivir showed no inhibition to bacterial sialidases. Therefore, 
it will be interesting to examine and compare the inhibitory potential of other sialidase 
inhibitor analogues, such as 4-substituted Neu5Ac2en derivatives, to a variety of 
Bacteroides-derived sialidases. The potent sialidase inhibitor in reducing the outgrowth of E. 
coli during inflammation may also be used as a potential treatment against other diseases 
triggered by pathogenic E. coli in gastrointestinal or urinal tract infection. 
 
Overall, the advancement of glycomics is now making it more feasible to study the complex 
glycome in response to environmental or microbial stimuli. The longitudinal analysis of 
mucosal glycome and microbiome helps us to better understand host-microbiota interaction 
in a variety of intestinal inflammatory diseases. In particular, it might be of a great promise to 
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develop a novel therapeutic by regulating glycan metabolic pathway. 
 
The role of gut microbiota in mucosal immunity 
 
The impact of the gut microbiota on mucosal immunity is widely studied in the context of 
IBD. Accumulating evidences suggest the essential contribution of gut microbiota in driving 
inflammation in IBD. However, characterization of the specific microbial signature with 
disease is greatly influenced by inter-individual variability, such as genetic background and 
individual’s gut microbiome [18]. The studies based on discordant disease status of twin pairs 
may be a valuable approach to address this question. Microbial alteration in CD patients 
confirmed the reduction of bacterial diversity and disappearance of core bacteria, including 
Faecalibacterium and Roseburia, as well as expansion of Enterobacteriaceae [19]. Notably, 
both Faecalibacterium and Roseburia spp. belong to butyrate-producing bacteria, which 
exhibit potent anti-inflammatory effects in mouse model [20]. By contrast, 
Enterobacteriaceae, in particularly E. coli, are associated with disease progression, 
reproducibly observed in patients with both UC and CD. 
 
Our microbial analysis based on murine colitis model also identified an increased abundance 
of Enterobacteriaceae in colitogenic mice. Further isolation of dominant bacteria and 
real-time PCR analysis confirmed the expansion of E. coli strain in colitogenic mice. 
Commensal E. coli is the most prominent aerobic bacteria colonized in the vicinity to the 
colonic mucosa and is believed to establish a colonization barrier against pathogenic invaders. 
The beneficial effects of E. coli have been proven in several randomized controlled clinical 
studies in which the maintenance of remission by E. coli strain Nissle 1917 is equivalent to a 
standard mesalazine treatment in IBD patients [21-22]. The strain-specific characteristic of E. 
coli Nissle 1917 is a point mutation in the gene for LPS O-antigen synthesis, leading to a 
repeating O6 subtype antigen structure and a unique immunomodulating effect [23]. 
Additionally, E. coli Nissle 1917 shows strong vitality and fitness by expressing enterobactin 
for efficient iron uptake and H1 flagella for increasing mobility [24]. The expression of 
enterobactin has been recently confirmed as a survival advantage for E. coli to surpass host 
immune system during intestinal inflammation [25]. 
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However, the phenotypes of E. coli are extremely diverse, some of the E. coli strains cause 
severe infections in humans, such as enteroinvasive E. coli (EIEC), enteropathogenic E. coli 
(EPEC), enterotoxigenic  E. coli (ETEC). Differentiation among these pathogenic E. coli 
requires detection of specific virulence factors. However, by PCR analysis, we did not detect 
any specific virulence genes including heat-labile enterotoxin (LT), heat-stable enterotoxin 
(STII), shiga-toxin (Stx), invasion plasmid antigen H (ipaH) and intimin (eae) in our E. coli 
isolate (EHV2) from colitogenic mice. This might explain why the reconstitution of EHV2 to 
WT mice did not directly drive the intestinal inflammation. Interestingly, we found that EHV2 
harbors a 4.6 kbp plasmid encoding gene homologous to colicin. Colicin is a plasmid-encoded 
protein toxin produced by, and active against, E. coli or related species. Colicin is released 
into extracellular medium and forms a pore structure in inner membrane thereby exerts 
cytotoxic effect to other bacteria [26]. EHV2 harbors colicin-encoded plasmid most likely in 
order to reduce the growth competition against other bacteria. However, whether EHV2 
strain also influences on host mucosal immunity needs to be further investigated. 
Characterization of specific E. coli serotype (O, H and K antigens) and whole-genome 
sequencing allow us to better understand the uniqueness of this isolate strain.  
 
Conclusion and future perspective 
Glycosylation is a key post-translational modification of proteins and lipids, and plays 
essential roles in regulating a variety of physiological pathways. Structural complexity of the 
glycans hampers the elucidation of the interplay between host glycosylation and the gut 
microbiota in gastrointestinal physiology. Taking advantage of advancement in glycan 
synthesis and next-generation sequencing, we demonstrate for the first time that 
host-derived sialylation confers a critical growth advantage for E. coli during intestinal 
inflammation, and unravel a fundamental mechanism how glycan metabolism shapes the gut 
microbiota.  
 
However, no evidence gathered to date suggested that a single bacterial strain can directly 
initiate the onset of inflammatory bowel disease. Therefore, a large-scale and longitudinal 
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analysis of microbiota composition in IBD patients is required to evaluate the contributions 
of the gut microbiota on IBD pathogenesis. In addition to bacteria, fungi and viruses also 
compose the human gut microbiota, thereby should not be neglected in the investigation 
[27]. Recent studies have demonstrated interactions between enteric fungi and host innate 
immunity and also identified that a genetic polymorphism of fungal recognition is correlated 
with the severe form of UC [28]. Additionally, emerging evidence has revealed that the 
enteric virome is altered in patients with IBD, with disease specific changes observed 
between UC and CD [29]. The increasing richness and diversity of enteric virome, in particular, 
a marked expansion of bacteriophages was observed in IBD patients, thereby may affect the 
diversity of the gut bacteria [30]. Future studies will be focused on elucidating the complex 
interplay between Fungal, viral, and bacterial community, and their contributions to the host 
immune system and disease pathogenesis.  
 
Taken together, variations in diet, host genetics, and environmental stimuli create a dynamic 
and heterogeneous environment for the microbial community in the gut. Attempts to 
characterize the fluctuations of host glycosylation and the gut microbiota between healthy 
and disease state can provide us potential opportunities to develop the diagnostic tools and 
relevant therapies for intestinal inflammatory diseases. 
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